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STILBENE ANALOGS AND METHODS OF
TREATING CANCER

radation. Although these agents inhibit W nt signaling in normal cells and some APC-mutated colon cancer cells, they
may not be effective in colon cancer cells containing ~-cate
nin mutations. Several other Wnt inhibitors have also been
reported. However, side effects limit their potential use in
hnmans. Natural products found in foods are potentially ideal
chemopreventive and therapeutic agents for cancer if they
possess sufficient potency and minimal toxicity.
Therefore, there is an ongoing need for compounds that are
more potent than resveratrol and pterostilbene and that can be
used to treat cancer and other ailments. There is also a particular need for compounds that do not exhibit deleterious
side effects.

CROSS-REFERENCE TO RELATED
APPLICATION
This application is a Divisional ofU.S. application Ser. No.
13/360,109, filed on Jan. 27,2012, which claims the benefit of
both U.S. Provisional Application No. 61/437,341 filed Jan.
28, 2011 and U.S. Provisional Application No. 61/439,118,
filed Feb. 3, 2011, the entire disclosures of which are incorporated by reference herein.

5

10

SEQUENCE LISTING
15

The application contains a Sequence Listing which has
been submitted in ASCII format via EFS-Web and is hereby
incorporated by reference in its entirety. The Sequence Listing was previously submitted in parent application Ser. No.
13/360,109. Said ASCII copy, created on May 14, 2014, is
named SequenceListing_050229_0626.txt, and it is 5,375
bytes in size.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH

20

25

This invention was made with govermnent support under
2P20 RR020171 awarded by The National Institutes of
Health. The government has certain rights in the invention.
30

TECHNICAL FIELD
The present disclosure is directed to compounds having
antineoplastic activity. In particular, the disclosure is directed
to halogenated stilbene analogs and methods of identifying
the specific molecular target of the stilbene analogs and inhibiting cancer cell growth in a patient by administering the
stilbene analogs to the patient. Additionally, the present disclosure is directed to the direct target of stilbene analogs,
methionine adenosyltransferase 2A (MAT2A), and methods
of detecting the levels of MAT2A in a complex protein mixture.

Advantages of the present disclosure include halogenated
stilbene analogs and compositions having antineoplastic
activity and methods of inhibiting cancer cell growth and/or
treating cancer in a patient by administering one or more of
the halogenated stilbene analogs or compositions.
One aspect of the present disclosure is directed to halogenated stilbene analogs that are useful for killing hyperproliferating cells such as cancer cells for the treatment of human
malignant and benign cancers, including without limitation,
colorectal cancer (CRC), liver and breast cancer. In this
aspect of the disclosure, there are provided certain halogenated stilbene analogs having anti-neoplastic activity against
cancerous cells. The halogenated stilbene analogs of the
present disclosure include compounds according to formula
(I):
X-Ar1---'=Ra=CRb-Ar2

35

40

BACKGROUND
45

Resveratrol (trans- or (E)-3,5,4'-trihydroxystilbene (1))
(FIG. 1) is a phytoalexin produced in plants and popularized
as a beneficial ingredient of red wine. Resveratrol, its cis- or
(Z)-isomer (2), and another stilbene derivative, pterostilbene
(3), exhibit some anti-cancer activity. (FIG. 1) Recently, we
found that resveratrol and pterostilbene, a stilbene found in
blueberries, inhibit colon cancer cells at least partially
through inhibiting Wnt/~-catenin signaling. Zhang, W. eta!.,
J Med Chern 2011, 54, 1288-97.
Wnt/~-catenin signaling plays an important role in development and tnmorigenesis, and the deregulation ofWnt signaling results in formation of tumors. Over 90% of colorectal
cancers contain a mutation in APC or ~-catenin, and these
mutations stabilize ~-catenin and activate Wnt signaling.
Cells containing these mutations constitutively activate Wnt
signaling and undergo strong proliferation that ultimately
leads to cancer. Intercepting and blocking the Wnt/~-catenin
pathway at various points in the signaling cascade is an attractive target for colon cancer chemoprevention and therapeutics.
Several Wnt inhibitors have been identified that target the
upstream signaling of ~-catenin and promote ~-catenin deg-

SUMMARY OF THE DISCLOSURE

50

(I)

6

wherein Ra and R are independently H, alkyl, halo, alkoxy,
cyano; X represents at least one halogen, e.g., a fluorine,
chlorine, bromine, or iodine substituent, on Ar 1 ; each of Ar 1
and Ar2 are aryl, e.g., phenyl, naphthyl, and heteroaryl, e.g.,
pyridyl, pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl,
which can be further substituted with halo, amino, alkylamino, dialkylamino, arylalkylamino, N-oxides of dialkylamino, trialkylarmnoninm, mercapto, alkylthio, alkanoyl,
nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl,
sulfonyl,
sulfonamide,
CONR 11 Rw
NR 11 CO(R 13 ),
NR 11 COO(R 13 ), NR 11 CONR 12R 13 where R 1 u R 12 , R 13 , are
independently, H, alkyl, aryl, heteroaryl or a fluorine; provided thatAr2 contains at least one nitrogen atom in the aryl
ring or at least one nitrogen substituent on the aryl ring; e.g.,
an NRcRdz substituent where Rc is H, alkyl, alkoxy, aryl,
heteroaryl, Rd is an alkyl group, Z is a an unshared pair of
electrons, H, alkyl, oxygen; or a pharmaceutically acceptable
salt thereof.
In another embodiment of the present disclosure, the halogenated stilbene analogs include compounds of formula (II):

55

(II)

60

65

or a pharmaceutically acceptable salt thereof, wherein each of
Ra and R6 are as defined above;

US 9,132,102 B2
3
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R 1 to R 10 are independently H, halo, amino, alkylamino,
dialkylamino, N-oxides of dialkylamino, arylalkylamino,
dialkyloxyamino, trialkylammonium, mercapto, alkylthio,
alkanoyl, nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, sulfonamide, CONR 11 Rw NR 11 CO(R 13 ),
NR 11 COO(R 13 ), NR11 CONR 12 R 13 where R 1 u Rw R 13 , are
independently, H, alkyl, aryl, heteroaryl or a fluorine; provided at least one of R 1 to R 5 is a halogen, e.g. a fluorine
and/or chlorine; and at least one of R 6 to R 10 is a nitrogen
containing substituent, e.g., an NR'Rdz substituent where Rc
isH, alkyl, alkoxy, aryl, heteroaryl, Rd is an alkyl group, Z is
a an unshared pair of electrons, H, alkyl, oxygen.
In another embodiment of the present disclosure, the halogenated stilbene analogs include compounds according to
formula (III):

and colorectal cancers, which tend to occur more in older
individuals, e.g., 65 years or older.
In another aspect of the present disclosure, there is provided a method for disrupting Wnt signaling and/or other
pathways using inhibitors of the enzyme, methionine S-adenosyltransferase, in a cell by treating the cell with an effective amount of a halogenated stilbene analog. These analogs
can inhibit methionine adenosyltransferase 2A (MAT2A) and
reduce cellular S-adenosyl-methionine (SAM), which is a
major donor of DNA methylation and protein methylation
that regulate gene expression and tumor growth. SAM is also
a key factor in metabolic pathways. Thus, the halogenated
stilbene analogs described in the present disclosure are also
drug candidates for treatment of metabolic diseases, such as
diabetes.
The present disclosure further encompasses a pharmaceutical composition including one or more compounds of formula (I), formula (II) and/or formula (III) and/or one or more
pharmaceutically acceptable salt, solvate, hydrate, prodrug or
metabolite thereof, for treatment of a disorder associated with
an increased MAT2A biological activity or levels. In a related
embodiment, the disorder associated with an increased
MAT2A biological activity or levels is cancer. In another
embodiment, the cancer is colon cancer, breast cancer, lung
cancer, prostate cancer or liver cancer.
The present disclosure is also directed to a method of
treating a disorder associated with an increased methionine
adenosyltransferase 2A (MAT2A) biological activity or levels in a subject including administering to the subject an
effective amount of one or more compounds of formula (I)(III) and/or one or more pharmaceutically acceptable salt,
solvate, hydrate, prodrug or metabolite thereof. In another
embodiment, the present disclosure is directed to a method of
treating a disorder associated with an increased MAT2A biological activity or levels in a subject including administering
to the subject an effective amount of a composition including
one or more compounds of formula (I)-(III) and/or one or
more pharmaceutically acceptable salt, solvate, hydrate, prodrug or metabolite thereof. In a related embodiment, the
disorder associated with an increased MAT2A biological
activity or levels is cancer. In another related embodiment, the
cancer is colon cancer, breast cancer, lung cancer, prostate
cancer or liver cancer.
The present disclosure is also directed to a method of
modulating MAT2A activity in a subject, the method including administering to the subject an effective amount of one or
more compounds offormula (I), formula (II) and/or formula
(III) and/or one or more pharmaceutically acceptable salt,
solvate, hydrate, prodrug or metabolite thereof. In a related
embodiment, the modulation of MAT2A activity includes
decreasing MAT2A biological activity or level in a subject. In
another related embodiment, the modulation of MAT2A
activity includes decreasing SAM and/or S-adenosylhomocysteine (SAH) synthesis.
The present disclosure is also directed to a method of
detecting the levels of MAT2A in a complex protein sample,
said method includes contacting a detectably labeled compound of formula (I)-(III) to said complex protein mixture
under conditions whereby said labeled compound binds to
MAT2A present in the sample; isolating the bound MAT2A;
removing any unbound proteins and detecting the level of the
MAT2A bound to the detectably labeled compound in the
sample. In a related embodiment, the isolation of the bound
MAT2A is carried out by an affinity-based separation
method. In another related embodiment, the compound of
(I)-(III) is biotinylated. In another related embodiment, the
detection is conducted by western blot, HPLC, FPLC, ion
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or a pharmaceutically acceptable salt thereof, where, R 2 , R 3 ,
R 5 , R 6 , R 7 , R 9 , R 10 , Ra, R 6 and NRcRdz are the same as
defined above.
The present disclosure also encompasses biotinylated derivates of the halogenated stilbene analogs and metabolites of
the halogenated stilbene analogs.
The present disclosure further encompasses pharmaceutical compositions of the halogenated stilbene analogs, e.g.,
one or more compounds of formula (I), formula (II) and/or
formula (III) and/or one or more pharmaceutically acceptable
salts of compounds according to formulas (I), (II) and/or (III),
in combination with a pharmaceutical carrier. In one aspect of
the present disclosure, the pharmaceutical compositions
comprise an effective amount of at least one halogenated
stilbene analog.
The present disclosure is further directed to methods of
treating cancer, e.g., inhibiting cancer cell growth and/or
inhibiting tumor growth in a mammal, such as a human, or
treating diseases associated with hyperproliferating cells. In
one embodiment of this aspect of the disclosure, a therapeutically effective amount of one or more halogenated stilbene
analogs, pharmaceutical salts and/or compositions thereof is
administered to a patient in need of treatment of cancer sufficient to treat/inhibit cancer cell growth in the patient.
In another embodiment of this aspect of the disclosure, a
therapeutically effective amount of one or more halogenated
stilbene analogs, pharmaceutical salts and/or compositions
thereof sufficient to inhibit the cancer cell growth in a patient
is administered to a patient suffering from colorectal cancer.
In another embodiment, a therapeutically effective amount of
one or more halogenated stilbene analogs, pharmaceutical
salts and/or compositions thereof sufficient to inhibit or treat
breast cancer.
In yet another embodiment, a therapeutically effective
amount of one or more halogenated stilbene analogs, pharmaceutical salts and/or compositions thereof sufficient to
inhibit the cancer cell growth in a patient is administered to a
patient suffering from age-related cancer. Non-limiting
examples of age-related cancers include prostate, breast, lung
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exchange, size exclusion, fluorescence spectroscopy, UV-Vis
spectrometry or mass spectrometry.
The present disclosure is further directed to a method of
diagnosing cancer in a subject, including: (1) obtaining a
sample comprising protein from the subject, (2) contacting a
detectably labeled compound of formula (I)-(III) with proteins in the sample to bind to MATA2 and detect the level of
MAT2A in said sample; and (3) comparing the levels of
MAT2A in the sample to that of a normal reference, whereupon if the level of MAT2A in the sample is statistically
higher than that of the normal reference, a diagnosis of cancer
is indicated. In a related embodiment, the detection in step (2)
is carried out according to the method described in the preceeding paragraph. In another related embodiment, the
sample obtained from a subject is a biopsy sample including
cancer cells selected from breast, prostate, colorectal, lung,
colon, bladder, head and neck, intestine, ovarian, or skin
cancer cells.
The present disclosure further relates to a method of identifYing a subject who is a candidate for receiving treatment
with one or more compounds of formula (I), formula (II) or
formula (III) or one or more pharmaceutically acceptable salt,
solvate, hydrate, prodrug or metabolite thereof; said method
includes (1) obtaining a protein sample from the subject, (2)
contacting a detectably labeled compound of formula (I)-(III)
with proteins in the sample to bind to MATA2 and detect the
level ofMAT2A in said sample; and (3) comparing the level
ofMAT2A in the sample to that in a normal reference, whereupon if the level of MAT2A in the sample is statistically
higher than that of the normal reference, the candidacy of the
subject for treatment with compounds of formula (I), formula
(II) or formula (III) or one or more pharmaceutically acceptable salt, solvate, hydrate, prodrug or metabolite thereof is
indicated. In a related embodiment, the detection in step (2) is
carried out according to the method described in the above
paragraph describing detecting the levels ofMAT2A in complex protein sample.
The present disclosure is further directed to kit including
the compounds of the present disclosure. In a related embodiment, the kit includes one or more compounds of formula
(I)-(III). I another embodiment, the kit includes a composition including one or more compounds of formula (I)-(III)
and/or one or more pharmaceutically acceptable salt, solvate,
hydrate, prodrug or metabolite thereof. In a related embodiment, the kit includes one or more other therapeutic compounds or compositions for use in combination therapies.
In another embodiment, the kit can be a diagnostic kit
including a detectably labeled compound offormula (I)-(III)
for use as a diagnostic reagent. In another related embodiment, the labeled compound is biotinylated derivative of one
or more compounds of formula (I), formula (II) and/or formula (III). In another embodiment, the kit includes a binding
partner of the label of the labeled compound of formula
(I)-(III).
Additional advantages of the present disclosure will
become readily apparent to those skilled in this art from the
following detailed description, wherein only the preferred
embodiment of the disclosure is shown and described, simply
by way of illustration of the best mode contemplated of carrying out the disclosure. As will be realized, the disclosure is
capable of other and different embodiments, and its several
details are capable of modifications in various obvious
respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as
illustrative in nature, and not as restrictive.
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Reference is made to the attached drawings, wherein elements having the same reference numeral designations represent similar elements throughout and wherein:
FIG.l shows the structures of naturally occurring stilbenes
with antineoplastic activity. Structure 1 is a trans-resveratrol,
2 is cis-resveratrol and 3 is pterostilbene.
FIG. 2 is a schematic drawing of the general synthesis of
certain stilbene analogs and 1,2-diarylethanes. Legend: a, (1)
n-BuLi, THF; (2)ArCHO; b, (1) NaH, DMF; (2)ArCHO; c,
H 2 , Pd---C, THF.
FIG. 3 shows the chemical structures of several potential
metabolites of fluorinated and/or chlorinated stilbene analogs
of the present disclosure.
FIG. 4 is a schematic drawing of the synthesis of biotin
derivatives of the halogenated stilbene analogs. Legend: a,
SnC1 2 , HCl, HOAc; b, CNBr; c, biotinyl chloride, Et3N, THF;
d, biotin, HOBt, EDC, Et 3 N, DMF; e, ( +)-biotinyl-iodoacetamidyl-3,6-dioxaoctanediamine, K 2 C0 3 , EtOH.
FIG. S(A) provides the chemical structures of various
monofluorinated stilbenes of the present disclosure. FIG.
S(B) is a Western blot showing 4-aminostilbene (4c) represses
Wnt target genes at 30 f.LM. FIG. S(C) is a Western blot
showing 4-styryl-N,N-dimethylaniline (4d) is more active
than 4-methoxystilbene (4b) at 30 f.LM. FIG. S(D) is a Western
blot showing 4-(2-fluorostyryl)-N,N-dimethylaniline (4e)
and 4-(3-fluorostyryl)-N,N-dimethylaniline (40 represses
Wnt target genes at 10 f.LM. FIG. S(E) is a Western blot
showing the effect of the dimethylaminophenyl group within
4e. FIG. S(F) is a graph showing the potency of (4e) in
comparison to that of resveratrol and pterostilbene in inhibiting the proliferation ofCRC cells.
FIG. 6(A) provides the chemical structures of several dihalogenated N,N-dialkylaminostilbene analogs 4 and a saturated analog 5r of the disclosure. FIG. 6(B) is a Western blot
showing that dihalogenated N,N -dimethylaminostilbenes 4o,
4m and 4r, repress W nt target genes at 10 f.LM. FIG. 6( C) is a
Western blot showing that the ortho- and meta-isomers of
N,N -dimethylamino analogs (4p and 4q) are not as active as
the para-isomer (4r). FIG. 6(D) is a Western blot showing that
trihalogenated N,N-dimethylaminostilbene analogs (4v and
4w) are active Wnt inhibitors. FIG. 6(E) is a Western blot
demonstrating that compound 4r represses Wnt target genes
at 0.5 f.LM.
FIG. 7 demonstrates the effects of halogenated analogs of
the present disclosure on CRC cell proliferation in vitro and in
vivo. FIG. 7(A) is a graph showing inhibition of CRC cell
proliferation at 0.1, 0.3 and 1 f.LM of various compounds of the
disclosure. FIG. 7(B) shows representative nude mice treated
with compound 4r or corn oil after injection with LS 17 4 CRC
cells (2x1 0 6 ) subcutaneously into both flanks. FIG. 7(C) is a
graph of the body weights of nude mice treated with compound 4r and corn oil. FIG. 7(D) is a graph of tumor volume
in mice treated with compound 4r or corn oil. Statistical
significance was calculated by the student's t test (*p<0.05).
FIG. S(A) is a bar graph showing fluorescence at 365 nM
detected by Promega GloMax® Luminometer. FIG. S(B) is a
Western blot showing compound 4s is an active Wnt inhibitor.
S(C) is a Western blot showing that compound 4r (10 f.LM) and
resveratrol (100 f.LM) reduced the protein levels of Wnt/~
catenin targets in LS174 cells. FIG. S(D) is a Western blot
showing that compound 4r represses transcription of Wnt
target genes.
FIG. 9 relates to affinity purification of stilbene analog
target. FIG. 9(A) shows a biotinylated derivative 13 of a
halogenated stilbene analog of the present disclosure. FIG.
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9(B) shows silver staining of protein markers (1), elutions
ods for the treatment or prevention of disorders associated
with MAT2A. Such diseases or disorders include, but not
from Biotin-stilbene analog-beads (2), Streptavidin beads
limited to, proliferative disorders such as cancer or metabolic
alone (3) and unrelated biotin-labeled beads (4).
disorders such as diabetes, heart disease, aging, obesity, and
FIG. 10 shows halogenated stilbene analogs of the present
disclosure directly interacted with MAT2A. GST-MAT2A 5 neurodegenerative disorders such as Alzheimer and Parkinson diseases.
and GST-MAT2B fusion proteins were expressed and puriDefinitions
fied from E. coli. These proteins were incubated with streptaThe term "alkyl" is art-recognized, and includes saturated
vidin beads with or without biotinylated derivative 13. The
aliphatic groups, including straight-chain alkyl groups,
binding proteins were eluted by 2.5 mM D-biotin and ana10 branched-chain alkyl groups, cycloalkyl (alicyclic) groups,
lyzed by Western blot with an anti-GST-Ab.
alkyl substituted cycloalkyl groups, and cycloalkyl substiFIG. 11 shows that halogenated stilbenes are more potent
tuted alkyl groups. In certain embodiments, a straight chain or
than resveratrol in inhibiting the MAT2A activity in producbranched chain alky I has about 30 or fewer carbon atoms in its
ing SAM and SAH. FIG. llA shows the effects of 10 f.LM of
backbone (e.g., C 1 -C 30 for straight chain, C 3 -C 30 for
compound 4r versus 30 f.LM of resveratrol on SAM levels in
LS174 colon cancer cells. FIG.llB shows the effects of3 f.LM 15 branched chain), and alternatively, about 20 or fewer. Likewise, cycloalky Is have from about 3 to about 10 carbon atoms
of compound4dd and 10 f.LM of compound 4rversus 30 f.LM of
in their ring structure, and alternatively about 5, 6 or 7 carbons
resveratrol on SAM levels in colon cancer cells. FIG. llC
in the ring structure. The term "alkyl" as used herein also
shows the effects of 3 f.LM of compound 4dd and 10 f.LM of
includes halosubstituted alkyls.
compound 4r versus 30 f.LM of resveratrol on SAH levels in
The term "aralkyl" is art-recognized and refers to an alkyl
20
colon cancer cells.
group substituted with an aryl group (e.g., an aromatic or
FIG. 12 shows that MAT2A and MAT2B are essential for
heteroaromatic group).
cancer cell proliferation and their inhibition at a transcription
The terms "alkenyl" and "alkynyl" are art-recognized and
level reduces cancer cell proliferation. Knocking down
refer to unsaturated aliphatic groups analogous in length and
MAT2A gene (12A) and MAT2B gene (12B) with shRNAs
are shown to inhibit proliferation of liver cancer cell line 25 possible substitution to the alkyls described above, but that
contain at least one double or triple bond respectively.
Hep3B (12C).
Unless the number of carbons is otherwise specified,
FIG. 13 shows a time-course study for the effects of the
"lower alkyl" refers to an alkyl group, as defined above, but
MAT2A and MAT2B genes inhibition on the proliferation of
having from one to about ten carbons (C 1 -C 10), e.g., from one
colon cancer cells. FIG. 13A shows inhibition of the HT29
cell proliferation by MAT2A and MAT2B shRNAs. FIG. 13B 30 to about six carbon atoms (C 1 -C 6 ) in its backbone structure.
Likewise, "lower alkenyl" "loweralkyl, "lower amino",
shows inhibition of the LS 17 4 T cell proliferation by MAT2A
"lower alkynyl", etc. have similar chain lengths.
and MAT2B shRNAs.
The term "unit dose" or "dosage" refers to physically disFIG. 14 is a chart showing that the halogenated stilbene
crete units suitable for use in a subject, each unit containing a
analogs of the present disclosure inhibit proliferation of colon
35 predetermined-quantity of the therapeutic composition calcancer cells.
culated to produce the desired responses discussed above in
FIG. 15 is a chart illustrating that the halogenated stilbene
association with its administration, i.e., the appropriate route
analogs of the present disclosure inhibit proliferation ofliver
and treatment regimen. The quantity to be administered, both
cancer cells.
according to number of treatments and unit dose, depends on
FIG. 16 is a chart showing the effect of the halogenated
stilbene 4dd toward inhibition of xenograft tumors in nude 40 the protection or effect desired.
The term "treat" and "treatment" refer to both therapeutic
m1ce.
treatment and prophylactic or preventative measures, wherein
FIG. 17 shows the inhibitory effects of selected halogethe object is to prevent or slow down (lessen) an undesired
nated stilbene analogs on proliferation ofbreast cancer (17A),
pathological change or disorder, such as the development or
lung cancer (17B and 17C), carcinoid tumor (17D) and pros45 spread of cancer. For purpose of this disclosure, beneficial or
tate cancer (17E) cell lines.
desired clinical results include, but are not limited to, alleviaFIG. 18A shows a mutant MAT2A (K265L) that was pretion of symptoms, diminishment of extent of disease, stabipared to conduct binding studies for the halogenated stilbene
lized (i.e., not worsening) state of disease, delay or slowing of
analogs. FIG. 18B shows that a terminal deletion ofMAT2A
disease progression, amelioration or palliation of the disease
(MAT2A-short) does not affect the binding of the halogenated stilbene analogs to MAT2A. FIG. 18C shows that 50 state, and remission (whether partial or total), whether detectable or undetectable. For example, "treatment" can include a
mutant MAT2A (MAT2A-K265L) partially loses its ability to
qualitative or quantitative reduction (e.g., by at least 10%,
bind to halogenated stilbene analogs.
20%,30%,40%,50%,60%,70%,80%,90%,95%, or more)
in the tumor or metastases size or reduce or prevent metastatic
DETAILED DESCRIPTION OF THE
55 growth. "Treatment" can also mean prolonging survival as
DISCLOSURE
compared to expected survival if not receiving treatment.
Those in need of treatment include those already with the
The present disclosure relates to novel inhibitors of the
enzyme methionine adenosyltransferase 2A (MAT2A) (Gecondition or disorder as well as those prone to have the
neiD: 4144; nucleotide NM_005911; amino acid ID:
condition or disorder or those in which the condition or disNP_005902). These compounds are useful for treating or 60 order is to be prevented.
The phrase "therapeutically effective amount" means an
preventing any disease and/or condition, wherein modulation
amount of a compound of the present disclosure that (i) treats
of MAT2A levels, and/or its enzymatic products (i.e., S-adenosyl-methionine (SAM or AdoMet)), is effective in ameor prevents the particular disease, condition, or disorder, (ii)
liorating symptoms or diseases Inhibition ofMAT2A can lead
attenuates, ameliorates, or eliminates one or more symptoms
to decrease in SAM levels and a reduction in the methylation 65 of the particular disease, condition, or disorder, or (iii) prereactions or methylated products downstream of SAM. Thus,
vents or delays the onset of one or more symptoms of the
the disclosure provides compounds, compositions and methparticular disease, condition, or disorder described herein. In
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the case of cancer, the therapeutically effective amount of the
drug may be reduce the number of cancer cells; reduce the
tumor size; inhibit (i.e., slow to some extent and preferably
stop) cancer cell infiltration into peripheral organs; inhibit
(i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to
some extent one or more of the symptoms associated with the
cancer. To the extent the drug may prevent growth and/or kill
existing cancer cells, it may be cytostatic and/or cytotoxic.
For cancer therapy, efficacy can be measured, for example, by
assessing the time to disease progression (TTP) and/or determining the response rate (RR).
The terms "cancer" and "cancerous" refer to or describe the
physiological condition in mammals that is typically characterized by unregulated cell growth. A "tumor" comprises one
or more cancerous cells. Examples of cancer include, but are
not limited to, carcinoma, lymphoma, blastoma, sarcoma,
and leukemia or lymphoid malignancies. More particular
examples of such cancers include squamous cell cancer (e.g.,
epithelial squamous cell cancer), lung cancer including
small-cell lung cancer, non-small cell lung cancer
("NSCLC"), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular
cancer, gastric or stomach cancer including gastrointestinal
cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatome, breast
cancer, colon cancer, rectal cancer, colorectal cancer,
endometrial or uterine carcinoma, salivary gland carcinoma,
kidney or renal cancer, prostate cancer, vulval cancer, thyroid
cancer, hepatic carcinoma, anal carcinoma, penile carcinoma,
as well as head and neck cancer.
The term "prodrug" as used in this application refers to a
precursor or derivative form of a compound of the disclosure
that may be less cytotoxic to cells compared to the parent
compound or drug and is capable of being enzymatically or
hydrolytically activated or converted into the more active
parent form. The prodrugs of this disclosure include, but are
not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs,
glycosylated prodrugs, ~-lactam-containing prodrugs,
optionally substituted phenoxyacetamide-containing prodrugs, optionally substituted phenylacetamide-containing
prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be converted into the more active cytotoxic
free drug.
A "metabolite" is a product produced through metabolism
in the body of a specified compound or salt thereof. Metabolites of a compound may be identified using routine techniques known in the art and their activities determined using
tests such as those described herein. Such products may result
for example from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.
The term "complex protein sample" is used to distinguish
a sample from a purified protein sample. A complex protein
sample contains multiple proteins, and may additionally contain other contaminants. Non-limiting examples of a complex
protein samples include tumor tissues, biopsy samples, serum
or cell extracts.
By "reference sample" is meant any sample, standard, or
level that is used for comparison purposes. A "normal reference sample" can be a prior sample taken from the same
subject, a sample from a subject not having cancer, a subject
that is diagnosed with cancer but not a metastatic disease, a
subject that has been treated for either cancer, metastatic
disease, or both, a subject that has a benign tumor, or a sample

of particular tissues from one or more healthy subjects, or a
pooled sample of tissues from one or more healthy subjects.
The phrase "biological activity of MAT2A" or "MAT2A
biological activity" as used herein, refers to all inherent biological properties of methionine adenosyltransferase 2A
(MAT2A) enzyme. Biological properties ofMAT2A include
but are not limited to catalyzing the transfer of the adenosyl
group of ATP to the sulfur atom of methionine and producing
S-adenosyl-methionine (SAM or AdoMet); involving in an
abnormal cell growth and proliferation in cancer cells; facilitating intracellular methylation reactions through the action
of SAM as a methyl group donor.
The term "labeled" or "detectably labeled" as used herein
means joining, either covalently or non-covalently to the
compounds of the present disclosure, a substance which elicits a physical or chemical response that can be observed or
detected by a binding partner such as biotin/streptavidin,
antigen/antibody or by means of instrumentation such as,
without limitation, UVNis spectrophotometers, flow cytometers, fluorescence detection instruments and the like, by the
naked eye. A wide variety of labels and labeling techniques
are well known in the art. Suitable labels include biotin,
radionuclides, e.g., 32P, 35S, 3H, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like.
The phrase "binds to" when referring to the binding of the
labeled compounds of the present disclosure to MAT2A for
detection purposes, refers to a binding reaction which is
determinative of the presence of the MAT2A in the presence
of a heterogeneous population of proteins and other biologics.
Thus, under binding assay conditions, for example, a labeled
compound of the present disclosure binds to MAT2A and
does not bind in a significant amount to other proteins present
in the sample. A variety of conventional detection means can
be used for detecting the binding of the labeled compounds to
MAT2A, such as western blot, flow cytometry and FACS
analysis, immunohistochemistry and the like. See, e.g., Harlow and Lane Anti bodies, A Laboratory Manual., Cold Spring
Harbor Publications, NY (1988) for a description of, e.g.,
western blot or immunofluorescence assay. Typically, a specific or selective binding reaction will be at least twice the
background signal or noise and more typically more than 10
to 100 times background.
Accordingly, the disclosure includes metabolites of compounds of the disclosure, including compounds produced by
a process comprising contacting a compound of this disclosure with a mammal for a period of time sufficient to yield a
metabolic product thereof.
Therapeutic Agents
Disclosed herein are halogenated stilbene analogs and their
use in mitigating hyperproliferating cells or treating diseases
or disorders associated with MAT2A activity. The halogenated stilbene analogs of the present disclosure display antitumor activity, i.e., cancer cells that are exposed to the compounds are killed, damaged and/or tumor growth is inhibited.
The analogs are useful for treatment of human cancers including colorectal cancer, liver, breast cancer, among others.
The halogenated stilbene analogs of the present disclosure
include compounds according to formula (I):
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X-Ar1---'=Ra=CRb-Ar2

(I)

where Ra and R 6 are independently H, alkyl, halo, alkoxy,
cyano; X represents at least one halogen, e.g., a fluorine,
chlorine, bromine, or iodine substituent, on Ar 1 ; each of Ar 1
and Ar2 are aryl, e.g., phenyl, naphthyl, and heteroaryl, e.g.,
pyridyl, pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl,
which can be further substituted with halo, amino, alky-
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!amino, dialkylamino, arylalkylamino, N-oxides of dialkylamino, trialkylammonium, mercapto, alkylthio, alkanoyl,
nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl,
NR 11 CO(R 13 ),
sulfonyl,
sulfonamide,
CONR 11 Rw
NR 11 COO(R 13 ), NR11 CONR 12 R 13 where R 1 v Rw R 13 , are
independently, H, alkyl, aryl, heteroaryl or a fluorine; provided that Ar2 contains at least one nitrogen atom in the aryl
ring or at least one nitrogen substituent on the aryl ring; e.g.,
an NR"Rdz substituent onAr2 where Rc isH, alkyl, alkoxy,
aryl, heteroaryl, Rd is an alkyl group, Z is a an unshared pair
of electrons, H, alkyl, oxygen. Preferably, the heteroaryl
group is a monocyclic ring, wherein the ring comprises 2 to 5
carbon atoms and 1 to 3 heteroatoms, referred to herein as
"(C 2 -C 5 ) heteroaryl". This embodiment also includes a pharmaceutically acceptable salt offormula (I) and a biotinylated
derivative of formula (I). The substituents on the carboncarbon double bond can be in either the cis- or trans-configuration. In one aspect of the present disclosure, X is one, two or
three fluorine substituents and/or X is one, two or three chlorine substituents and/or X represents at least one fluorine and
at least one chlorine on Ar 1 . In another aspect of the present
disclosure, X is one or more fluorine and/or chlorine and Rc is
H or a lower alkyl and Rd is a lower alkyl, or a pharmaceutically acceptable salt thereof, or a biotinylated derivative
thereof.
In another embodiment, the present disclosure includes
compounds of formula (II):

(III)
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where Ra and R6 are as defined above, R 1 to RIO are independently H, halo, amino, alkylamino, dialkylamino, N -oxides of
dialkylamino, arylalkylamino, dialkyloxyamino, trialkylammonium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, cyano,
alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, sulfonamide,
CONR 11 R 12 ,
NR 11 CO(R 13 ),
NR 11 COO(R 13 ),
NR 11 CONR 12R 13 where R 1 v R 12 , R 13 , are independently, H,
alkyl, aryl, heteroaryl or a fluorine; provided at least one ofR 1
to R5 is a halogen, e.g. a fluorine and/or chlorine; and at least
one ofR 6 to RIO is a nitrogen containing substituent, e.g., an
NRcRdz substituent where Rc isH, alkyl, e.g., a lower alkyl,
alkoxy, aryl, heteroaryl, Rd is an alkyl group, Z is a an
unshared pair of electrons, H, alkyl, oxygen, or a pharmaceutically acceptable salt thereof, or a biotinylated derivative
thereof.
In other embodiments of the present disclosure, at least one
of R 1 to R5 is a chlorine and/or fluorine substituent; at least
one ofR 6 to RIO is NRcRdz where Rc isH or lower alkyl and
Rdis a lower alkyl. In certain embodiments, one, two or three
ofR 1 to R5 is a fluorine or a chlorine group; while in certain
embodiments R 1 and R5 are each fluorine and/or chlorine
groups, e.g., R 1 and R5 are either two fluorine, two chlorine or
one each of fluorine and chlorine groups. In another embodiment R 1 and R4 are each fluorine and/or chlorine groups, e.g.
R 1 and R4 are either two fluorine, two chlorine or one each of
fluorine and chlorine groups.
In another embodiments, the present disclosure includes
compounds according to formula (III):
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whereRv R 2 , R3 , R5 , R 6 , R7 , R9 , RIO, Ra, R6 andNRcRdZare
the same as defined above, or pharmaceutically acceptable
salts thereof, or a biotinylated derivative thereof. In one
aspect of the present disclosure, Ra, R6 are both H, one or
more ofRv R 2 , R3 , or R5 , are fluorine or chlorine and Rc isH
or lower alkyl, such as a methyl, ethyl, propyl group, and Rd
is a lower alkyl, such as a methyl, ethyl, propyl group. In
another aspect of the present disclosure, Ra, R6 are both H,
and at least two of R 1 , R 2 , R3 , or R5 are fluorine and/or
chlorine, or a pharmaceutically acceptable salt thereof, or a
biotinylated derivative thereof.
In another embodiment of the present disclosure, the halogenated stilbene analog is a dihalogenated N,N -dimethylaminostyrene having at least one fluorine or chlorine is in the 2' or
3' position of the aryl ring. In another embodiment, the stilbene analog has a fluorine in the 2' position and another
fluorine in the 6' position. In another embodiment, the stilbene analog has a fluorine in the 2' position and a chlorine in
the 6' position. In another embodiment, the stilbene analog
has a chlorine in the 2' position and another chlorine in the 6'
position.
In another embodiment, the stilbene analog is a dihalogenated N-methylaminostyrene in with at least one fluorine or
chlorine is in the 2' or 3' position.
Particular halogenated stilbene analogs of the present disclosure include (E)-4-(2-Fluorostyryl)-N,N-dimethylaniline;
(E)-4-(3-Fluorostyryl)-N,N -dimethylaniline; (E)-4-(4-Fluorostyryl)-N,N-dimethylaniline; (E)-4-(2-Fluorostyryl)-N,Ndiethylaniline; (E)-4-(2-Fluorostyryl)-N,N-diphenyl aniline;
(E)-1-( 4-(2-Fluorostyryl)phenyl)-4-methylpiperazine; (E)4-(2-Fluorostyryl)-N,N -dimethylnaphthalen-1-amine; (E)2-( 4-(2-Fluorostyryl)phenyl)-1-methyl-1H-imidazole; (E)4-(2,3-Difluorostyryl )-N,N -dimethy!aniline;
(E)-4-(2,4Difluorostyryl)-N,N-dimethylaniline;
(E)-4-(2,5Difluorostyryl)-N,N-dimethylaniline;
(E)-2-(2,6Difluorostyryl)-N,N-dimethylaniline;
(E)-3-(2,6Difluorostyryl)-N,N-dimethylaniline;
(E)-4-(2,6(E)-4-(2,6Difluorostyry1)-N,N -dimethylaniline;
Difluorostyryl)-N,N-diethylaniline;
(E)-4-(3,4Difluorostyryl)-N,N-dimethylaniline;
(E)-4-(3,5Difluorostyryl)-N,N -dimethylaniline; (E)-N,N -Dimethyl-4(2,3,6-trifluorostyryl)aniline; (E)-N,N-Dimethyl-4-(2,4,6trifluorostyryl )aniline; (E)-4-(2-chloro-6-fluorostyry I)-N,Ndimethylaniline;
(E)-4-(2,6-dichlorostyryl)-N,Ndimethylaniline;
(E)-4-(2,6-Difluorophenethyl)-N,Ndimethylaniline;
and
(E)-2-benzamide-4-(2,6difluorostyryl )-N,N -dimethy!aniline.
Synthesis
The compounds of the present disclosure, including compounds of Formula (I) to Formula (III), may be prepared by
methods disclosed herein or any other method known in the
art. One of ordinary skill in the art will know how to modifY
procedures to obtain the analogs of the present disclosure. In

US 9,132,102 B2
13

14

addition, compounds may be prepared using the methods
described below and in Examples 1 through 3 or modified
versions thereof.
FIG. 2 is a schematic of the general synthesis of certain
halogenated stilbene analogs of the present disclosure. Additiona! halogenated stilbene analogs of the present disclosure
can be made by similar methods or known synthetic procedures known in the art in light of the present disclosure. For
example, as shown in FIG. 2 either Wittig or WadsworthEmmons reactions using phosphonium salts or diethyl phosphonates, respectively, with aldehydes provided the (E)-stilbenes (4) in good yield. The phosphonium salts were
prepared from the corresponding benzyl bromides and triphenylphosphine, and the diethyl phosphonates were prepared
from the corresponding benzyl bromides and triethyl phosphite using the Arbuzov reaction according to standard literature procedures. Compounds were characterized fully and
purity (>95%) established through combustion analyses.
The terms ortho, meta and para are art-recognized term and
refer to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively. For example, the names 1,2-dimethylbenzene and
ortho-dimethylbenzene are synonymous.
The present disclosure also encompasses potential metabolites of the halogenated stilbene analogs. These include stilbene analogs, e.g., general formulae (I), (II) or (III), having a
dialkyamino substituent which has undergone an oxidation to
anN -oxide. In one embodiment, the compound is theN -oxide
of the dihalogenated N,N-dimethylaminostyrene having at
least one fluorine or chlorine is in the 2' or 3' position. These
potential metabolites also include halogenated stilbene analogs having a N,N-dialkylamino group which has undergone
a methylation or a demethylation. In one embodiment, the
stilbene analog is a dihalogenated N,N,N-trimethylammoniumstyrene halide having at least one fluorine or chlorine is in
the 2' or 6' position. In one embodiment, the analog is a
dihalogenated N-methylaminostyrene having at least one
fluorine or chlorine is in the 2' or 3' position. In one embodiment, the analog is a dihalogenated N,N-methylhydroxyaminostyrene having at least one fluorine or chlorine in the 2' or
3' position.
The present disclosure also encompasses biotinylated
derivatives of the halogenated stilbene analogs. Such biotinylated derivatives are useful in identifYing the molecular
target for these agents. Stilbene analogs encompassed by
formulas (I), (II) and (III) were synthesized and converted to
biotinylated derivatives. The biotinylated derivatives that
retain biological activity were used to identify a molecular
enzyme target for these compounds, methionine S-adenosyltransferase.
In certain embodiments of the present disclosure, the halogenated stilbene analogs of the disclosure, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof,
inhibit the growth of hyperproliferative cells. In certain
embodiments of the present disclosure, the halogenated stilbene analogs of the disclosure, or a pharmaceutically acceptable salt, solvate, hydrate or pro drug thereof, inhibit methionine adenosyltransferase 2A (MAT2A) activity and are useful
in treating diseases or conditions associated with MAT2A,
e.g., diseases and conditions whose maintenance and/or
spread require MAT2A.
Metabolites of Compounds of the Disclosure
Also falling within the scope of this disclosure are the in
vivo metabolic products of formulas (I) to (III) described
herein. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of
the administered compound.

Accordingly, the disclosure includes metabolites of compounds of formulas (I) to (III), including compounds produced by a process comprising contacting a compound of this
disclosure with a mammal for a period of time sufficient to
yield a metabolic product thereof.
Metabolite products typically are identified by preparing a
detectably labeled, for example a radio labeled (e.g., C or H
isotope) compound of the disclosure, administering it
parenterally in a detectable dose (e.g., greater than about 0.5
mg/kg) to an animal such as rat, mouse, guinea pig, monkey,
or to man, allowing sufficient time for metabolism to occur
(typically about 30 seconds to 30 hours) and isolating its
conversion products from the urine, blood or other biological
samples. These products are easily isolated since they are
detectably labeled (others are isolated by the use of antibodies
capable of binding epitopes surviving in the metabolite). The
metabolite structures are determined in conventional fashion,
e.g., by MS, LC/MS or NMR analysis. In general, analysis of
metabolites is done in the same way as conventional drug
metabolism studies, which are well known to those skilled in
the art. The metabolite products, so long as they are not
otherwise found in vivo, are useful in diagnostic assays for
therapeutic dosing of the compounds of the disclosure.
Examples oflikely metabolites of compounds offormulas (I)
to (III) are shown in FIG. 3 and synthesized according to
Example 2.
Prodrugs of the Compounds of the Disclosure
In addition to compounds of the disclosure, the disclosure
also includes pharmaceutically acceptable prodrugs of such
compounds. Prodrugs include compounds wherein an amino
acid residue, or a polypeptide chain of two or more (e.g., two,
three or four) amino acid residues, is covalently joined
through an amide or ester bond to a free amino, hydroxy or
carboxylic acid group of a compound of the present disclosure. The amino acid residues include but are not limited to
the 20 naturally occurring amino acids commonly designated
by three letter symbols and also includes phosphoserine,
phosphothreonine, phosphotyrosine, 4-hydroxyproline,
hydroxyzine, demosine, isodemosine, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid,
statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,
penicillamine, ornithine, 3-methylhistidine, norvaline, betaalanine, gma-aminobutyric acid, citrulline, homocysteine,
homo serine, methy!-alanine, para -benzoy!phenylalanine,
phenylglycine, propargylglycine, sarcosine, methionine sulfone and tert-butylglycine.
Additional types of prodrugs are also encompassed. For
instance, a free carboxyl group of a compound of the disclosure can be derivatized as an amide or alkyl ester. As another
example, compounds of this disclosure comprising free
hydroxy groups may be derivatized as prodrugs by converting
the hydroxy group into a group such as, but not limited to, a
phosphate ester, hemisuccinate, dimethylaminoacetate, or
phosphoryloxymethyloxycarbonyl group, as outlined in
Advanced Drug Delivery Reviews, (1996) 19:1-15. Carbamate prodrugs of hydroxy and amino groups are also included,
as are carbonate prodrugs, sulfonate esters and sulfate esters
ofhydroxy groups. Derivatization ofhydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl
group may be an alkyl ester optionally substituted with
groups including, but not limited to, ether, amine and carboxylic acid functionalities, or where the acyl group is an
amino acid ester as described above, are also encompassed.
Pro drugs of this type are described in J. Med. Chern., (1996),
39:10. More specific examples include replacement of the
hydrogen atom with a group such as (C1-C6)alkanoyloxymethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6)
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alkanoy loxy )ethyl,
(C 1-C6)alkoxycarbonyloxymethy I,
N-(C 1-C6)alkoxycarbonylaminomethy I, succinoy I, (C 1C6)alkanoyl, a-amino(C1-C4)alkanoyl, arylacyl and a-aminoacyl, or a-aminoacyl-a-aminoacyl, where each a-aminoacyl group is independently selected from the naturally
occurring L-amina acids, P(O)(OH) 2 , -P(O)(O(C1-C6)
alkyl)2 or glycosyl (the radical resulting from the removal of
a hydroxyl group of the hemiacetal form of a carbohydrate).
For additional examples of prodrug derivatives, see, for
example, a) Design of Prodrugs, edited by H. Bundgaard,
(Elsevier, 1985) and Methods in Enzymology, Vol. 42, p.
309-396, edited by K. Widder, eta!. (Academic Press, 1985);
b) A Textbook of Drug Design and Development, edited by
Krogsgaard-Larsen and H. Bundgaard, Chapter "Design and
Application of Prodrugs," by H. Bundgaard p. 113-191
(1991); c) H. Bundgaard, Advanced Drug Delivery Reviews,
8:1-38 (1992); d) H. Bundgaard, eta!., Journal of Pharmaceutical Sciences, 77:285 (1988); and e) N. Kakeya, eta!.,
Chern. Pharm. Bull., 32:692 (1984), each of which is specifically incorporated herein by reference.
Pharmaceutical Compositions
The present disclosure also encompasses pharmaceutical
compositions comprising at least one halogenated stilbene
analog, e.g., one or more compounds of formula (I), formula
(II) and/or formula (III) and/or one or more pharmaceutically
acceptable salts of compounds according to formulae (I), (II)
and/or (III), in combination with a pharmaceutical carrier. In
one aspect of the present disclosure, the pharmaceutical compositions comprise an effective amount of at least one halogenated stilbene analog. In another embodiment of the
present disclosure, the pharmaceutical composition comprises a dihalogenated N,N-dialkylaminostilbene analog and
a pharmaceutically acceptable carrier.
While it may be possible for compounds of the present
disclosure to be administered as the raw chemical, it is preferable to present them as a pharmaceutical composition.
According to a further aspect, the present disclosure provides
a pharmaceutical composition comprising a compound or
mixture of compounds of Formula (I) to Formula (III) or a
pharmaceutically acceptable salt, solvate, hydrate, prodrug or
metabolite thereof, together with one or more pharmaceutical
carrier, excipient or additive and optionally one or more other
therapeutic ingredients. The carrier(s) must be "acceptable"
in the sense of being compatible with the other ingredients of
the formulation and not deleterious to the recipient thereof.
The term "pharmaceutically acceptable carrier" includes
vehicles and diluents.
To prepare the pharmaceutical compositions, a therapeutically effective amount of one or more of the halogenated
stilbene analogs according to the present disclosure may be
intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding
techniques to produce a dose. A carrier may take a wide
variety of forms depending on the form of preparation desired
for administration, e.g., oral, topical or parenteral, including
gels, creams ointments, lotions and time released implantable
preparations, among numerous others. In preparing pharmaceutical compositions in oral dosage form, any of the usual
pharmaceutical media may be used. Thus, for liquid oral
preparations such as suspensions, elixirs and solutions, suitable carriers and additives including water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the
like may be used. For solid oral preparations such as powders,
tablets, capsules, and for solid preparations such as suppositories, suitable carriers and additives including starches,
sugar carriers, such as dextrose, mannitol, lactose and related
carriers, diluents, granulating agents, lubricants, binders, dis-

integrating agents and the like may be used. If desired, the
tablets or capsules may be enteric-coated or sustained release
by standard techniques.
In one embodiment, the compositions are prepared with
carriers that will protect the active compound(s) against rapid
elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery
systems. Biodegradable, biocompatible polymers can be
used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
Methods for preparation of such formulations will be apparent to those skilled in the art.
The pharmaceutically acceptable carrier may take a wide
variety of forms, depending on the route desired for administration, for example, oral or parenteral (including intravenous). Carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders and
disintegrating agents may be used in the case of oral solid
preparations such as powders, capsules and caplets, with the
solid oral preparation being preferred over the liquid preparations. Preferred solid oral preparations are tablets or capsules, because of their ease of administration. If desired,
tablets may be coated by standard aqueous or nonaqueous
techniques. Oral and parenteral sustained release dosage
forms may also be used.
Liposomal suspensions may also be pharmaceutically
acceptable carriers. These may be prepared according to
methods known to those skilled in the art. For example, liposomal formulations may be prepared by dissolving appropriate lipid(s) in an inorganic solvent that is then evaporated,
leaving behind a thin film of dried lipid on the surface of the
container. An aqueous solution of the active compound is then
introduced into the container. The container is then swirled by
hand to free lipid material from the sides of the container and
to disperse lipid aggregates, thereby forming the liposomal
suspension. Other methods of preparation well known by
those of ordinary skill may also be used in this aspect of the
present disclosure.
In an embodiment, the composition of the present disclosure enables sustained, continuous delivery of a compound of
Formula (I) to Formula (III) or a pharmaceutically acceptable
salt, solvate, hydrate, prodrug or metabolite thereof, to tissues
adjacent to or distant from an administration site. The biologically-active agent is capable of providing a local or systemic biological, physiological or therapeutic effect. For
example, a compound of Formula (I) to Formula (III) or a
pharmaceutically acceptable salt, solvate, hydrate, prodrug or
metabolite thereof, may act to kill cancer cells, or cancer stem
cells or to control or suppress tumor growth or metastasis,
among other functions.
Formulations and Dosages for Administration
Pharmaceutical formulations based upon halogenated stilbene compounds of the present disclosure comprise at least
one of the compounds of Formula (I) to Formula (III) or a
pharmaceutically acceptable salt, solvate, hydrate, prodrug or
metabolite thereof, in a therapeutically effective amount for
treating neoplasia, cancer and other diseases and conditions
associated with MAT2A activity such as diabetes, heart disease, aging, obesity, Alzheimer's disease or Parkinson disease, optionally in combination with a pharmaceutically
acceptable additive, carrier and/or excipient. One of ordinary
skill in the art will recognize that a therapeutically effective
amount of one of more compounds according to the present
disclosure will vary with the condition to be treated, its severity, the treatment regimen to be employed, the pharmacokinetics of the agent used, as well as the patient (animal or
human) treated.
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The formulations of the present disclosure include those
suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intratumoral and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration, as well as those for
administration by inhalation. The most suitable route may
depend upon the condition and disorder of the recipient.
Exemplary formulations are well known to those skilled in
the art, and general methods for preparing them are found in
any standard pharmacy school textbook, for example, Remington: THE SCIENCE AND PRACTICE OF PHARMACY,
21st Ed., Lippincott. The formulations of the present disclosure may conveniently be presented in unit dosage form and
may be prepared by any of the methods well known in the art
of pharmacy. All methods include the step of bringing into
association a compound or a pharmaceutically acceptable salt
or solvate thereof ("active ingredient") with the carrier which
constitutes one or more accessory ingredients. In general, the
formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers
or finely divided solid carriers or both and then, if necessary,
shaping the product into the desired formulation. Oral formulations are well known to those skilled in the art, and general
methods for preparing them are found in any standard pharmacy school textbook, for example, Remington: THE SCIENCE AND PRACTICE OF PHARMACY, 21st Ed., the
entire disclosure of which is incorporated herein by reference.
The concentration of active compound of the present disclosure, i.e., at least one of the compounds of Formula (I) to
Formula (III) or a pharmaceutically acceptable salt, solvate,
hydrate, prodrug or metabolite thereof, in the drug composition will depend on absorption, distribution, inactivation, and
excretion rates of the drug as well as other factors known to
those of skill in the art. It is to be noted that dosage values will
also vary with the severity of the condition to be alleviated.
The composition may be administered at once, or may be
divided into a number of smaller doses to be administered at
varying intervals of time.
Oral compositions will generally include an inert diluent or
an edible carrier. They may be enclosed in gelatin-capsules or
compressed into tablets. For the purpose of oral therapeutic
administration, the active compound or its prodrug derivative
can be incorporated with excipients and used in the form of
tablets, troches, or capsules. Pharmaceutically compatible
binding agents, and/or adjuvant materials can be included as
part of the composition.
The tablets, pills, capsules, troches and the like can contain
any of the following non-limiting ingredients, or compounds
of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or
lactose, a dispersing agent such as alginic acid or corn starch;
a lubricant such as magnesium stearate; a glidant such as
colloidal silicon dioxide; a sweetening agent such as sucrose
or saccharin; or a flavoring agent such as peppermint, methyl
salicylate, or fruit flavoring. When the dosage unit form is a
capsule, it can contain, in addition to any of the above, a liquid
carrier such as a fatty oil. In addition, dosage unit forms can
contain various other materials which modifY the physical
form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
The tablets, for example, may optionally be coated or
scored and may be formulated so as to provide sustained,
delayed or controlled release of the active ingredient therein.
Oral and parenteral sustained release drug delivery systems
are well known to those skilled in the art, and general methods
of achieving sustained release of orally or parenterally admin-

istered drugs are found, for example, in Remington: THE
SCIENCE AND PRACTICE OF PHARMACY, 21st Ed.
The active compound may also be administered as a component of an elixir, suspension, syrup, wafer or the like. A
syrup may contain, in addition to the active compounds,
sucrose or fructose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
In certain embodiments of the present disclosure, the halogenated stilbene analog is formulated as admixture with a
pharmaceutically acceptable carrier, excipient or additive. In
general, the pharmaceutical composition is administered in
orally-administrable form, but for treatment of a number of
conditions, a number of other formulations may be administered via a topical, parenteral, intravenous, intramuscular,
transdermal, buccal, subcutaneous, suppository or other
route, including an eye or ocular route. Intravenous and intramuscular formulations are generally administered in sterile
saline. Of course, one of ordinary skill in the art may modify
the formulations within the teachings of the specification to
provide numerous formulations for a particular route of
administration without rendering the pharmaceutical compositions unstable or compromising their therapeutic activity. It
is also well within the mutineer's skill to modifY the route of
administration and dosage regimen of a particular compound
in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect to the patient.
In certain pharmaceutical dosage forms, the pro-drug form
of the compounds may be preferred. One of ordinary skill in
the art will recognize how to readily modifY the present
compounds to pro-drug forms to facilitate delivery of active
compounds to a targeted site within the host organism or
patient. The mutineer also will take advantage of favorable
pharmacokinetic parameters of the pro-drug forms, where
applicable, in delivering the present compounds to a targeted
site within the host organism or patient to maximize the
intended effect of the compound.
Pharmaceutical compositions containing any of the compounds of Formula (I) to Formula (III) or a pharmaceutically
acceptable salt, solvate, hydrate, prodrug or metabolite
thereof, may be conveniently presented in unit dosage form
and prepared by any of the methods well known in the art of
pharmacy. Preferred unit dosage formulations are those containing an effective dose, or an appropriate fraction thereof, of
the active ingredient, or a pharmaceutically acceptable salt
thereof. The magnitude of a prophylactic or therapeutic dose
typically varies with the nature and severity of the condition
to be treated and the route of administration. The dose, and
perhaps the dose frequency, will also vary according to the
age, body weight and response of the individual patient. In
general, the total daily dose (in single or divided doses) ranges
from about 0.1 mg per day to about 7000 mg per day, or about
0.1 mg per day to about 100 mg per day, or from about 10 mg
per day to about 100 mg per day, or from about 20 mg to about
100 mg, to about 80 mg or to about 60 mg. In some embodiments, the total daily dose may range from about 10 mg to
about 500 mg per day, or about 100 mg to about 500 mg per
day. It is further recommended that children, patients over 65
years old, and those with impaired renal or hepatic function,
initially receive low doses and that the dosage be titrated
based on individual responses and/or blood levels. It may be
necessary to use dosages outside these ranges in some cases,
as will be apparent to those in the art. Further, it is noted that
the clinician or treating physician knows how and when to
interrupt, adjust or terminate therapy in conjunction with
individual patient's response.
Alternatively, the maximum safe starting dose of the compounds of the present disclosure for use in initial clinical trials
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in adults may be determined by following, for example, the
FDA guidelines for estimating maximum safe dosage. These
guidelines provide guidance for using the dosages used in
animal studies to extrapolate safe dosage for use in human
trials. See Guidance for Industry, Estimating the Maximum
Safe Starting Dose in Initial Clinical Trials for Therapeutics
in Adult Healthy Volunteers, Food and Drug Administration,
Center for Drug Evaluation and Research (CDER), July 2005.
In an embodiment, the amount of compound included
within therapeutically effective formulations of the present
disclosure is an effective amount for treating the conditions
associated with MAT2A activity. In general, a therapeutically
effective amount of the present preferred compound in dosage form usually ranges from slightly less than about 0.025
mg/kg to about 2.5 g/kg, and in certain embodiments about
2.5 to about 5 mg/kg or about 2.5 to about 100 mg/kg of the
patient or considerably more, depending upon the compound
used, the condition being treated and the route of administration, although exceptions to this dosage range may be contemplated by the present disclosure. In some embodiments,
halogenated stilbene analogs of the present disclosure are
administered in amounts ranging from about 0.1 mg/kg to
about 100 mg/kg.
The active compound of the present disclosure, i.e., at least
one of the compounds of Formula (1) to Formula (III) or a
pharmaceutically acceptable salt, solvate, hydrate, prodrug or
metabolite thereof, is included in the pharmaceutically
acceptable carrier or diluent in an amount sufficient to deliver
to a patient a therapeutically effective amount for the desired
indication, without causing serious toxic effects in the patient
treated.
In certain embodiments, the active compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing 1 to 3000 mg, preferably
5 to 500 mg of active ingredient per unit dosage form. An oral
dosage of 10-250 mg is usually convenient.
The actual dosage amount of a composition of the present
disclosure administered to a patient or subject can be determined by physical and physiological factors such as body
weight, severity of condition, the type of disease being
treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. The
practitioner responsible for administration will, in any event,
determine the concentration of active ingredient( s) in a composition and appropriate dose(s) for the individual subject.
In certain embodiments, pharmaceutical compositions
may comprise, for example, at least about 0.1% of an active
compound, i.e., at least one of the compounds of Formula (I)
to Formula (III) or a pharmaceutically acceptable salt, solvate, hydrate, pro drug or metabolite thereof. In other embodiments, the active compound may comprise between about 1%
to about 7 5% of the weight of the unit, or between about 5%
to about 50%, for example, and any range derivable therein. In
other non-limiting examples, a dose may also comprise about
1 microgram/kg/body weight, about 5 microgram/kg/body
weight, about 10 microgram/kg/body weight, about 50
microgram/kg/body weight, about 100 milligram/kg/body
weight, about 150 milligram/kg/body weight, about 200 milligram/kg/body weight, about 300 milligram/kg/body
weight, about 400 milligram/kg/body weight or more per
administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed
herein, a range of about 50 microgram/kg/body weight to
about 50 milligram/kg/body weight, or from about 50 microgram/kg/body weight to about 50 milligram/kg/body weight,
etc., can be administered.

Route of Administration
In accordance with the methods of the present disclosure,
the described halogenated stilbene analogs of the present
disclosure or a pharmaceutically acceptable salt, solvate,
hydrate or prodrug thereof, may be administered to a subject
in a variety of forms depending on the selected route of
administration, as will be understood by those skilled in the
art. The active compound of the disclosure may be administered, for example, by oral, parenteral, buccal, sublingual,
nasal, rectal, patch, pump, or transdermal administration and
the pharmaceutical compositions formulated accordingly.
Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, intratumoral, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical
modes of administration. Parenteral administration may be by
continuous infusion over a selected period of time
Alternatively, the compounds of this disclosure may be
incorporated into formulations for any route of administration including for example, oral, topical and parenteral
including intravenous, intramuscular, eye or ocular, intraperitoneal, intrabuccal, transdermal and in suppository form.
Methods of Treatment
In an embodiment, the present disclosure is directed to
methods for treating a disorder associated with MAT2A biological activity in a subject comprising administering to the
subject an effective amount of a compound or composition of
one or more compounds of formula (I), formula (II) and/or
formula (III) and/or one or more pharmaceutically acceptable
salt, solvate, hydrate, prodrug or metabolite thereof.
In one embodiment, a MAT2A associated disorder is
tumors and/or cancer. Therefore, in an embodiment, the
present disclosure is also directed to methods for the treatment of tumors and/or cancer comprising administering an
effective amount of one or more halogenated stilbene analogs
of the present disclosure and/or a pharmaceutically acceptable salt, solvate, hydrate, prodrug or metabolite thereof to a
patient in need of such therapy. For example, the present
disclosure contemplates methods of treating various cancers
and complications thereof. More particularly, the present disclosure relates to methods for inhibiting the growth ofbenign
and malignant cancer, including a malignant tumor or cancer
comprising exposing the tumor to an inhibitory or therapeutically effective amount or concentration of at least one of the
halogenated stilbene analogs or pharmaceutically acceptable
salts or pharmaceutically acceptable composition thereof.
Treatment of internal malignancies such as eye or ocular
cancer, rectal cancer, colon cancer, cervical cancer, prostate
cancer, breast cancer, liver cancer and bladder cancer, and
age-related cancer among numerous others are contemplated
by the present disclosure.
Accordingly, the compounds and/or compositions of the
present disclosure are useful for treating animals, and in
particular, mammals, including humans, as patients. Thus,
humans and other animals, and in particular, mammals, suffering from hyperproliferative disorders, and in particular,
cancer, or other diseases as disclosed herein, can be treated by
administering to the patient an effective amount of one or
more of the halogenated stilbene analogs according to the
present disclosure, or its derivative or a pharmaceutically
acceptable salt thereof, optionally in a pharmaceutically
acceptable carrier or diluent, either alone, or in combination
with other known pharmaceutical agents (depending upon the
disease to be treated). Treatment according to the present
disclosure can also be by administration of the compounds
and/or compositions of the present disclosure in conjunction
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with other conventional cancer therapies, such as radiation
treatment or surgery or administration of other anti-cancer
agents.
In certain embodiments, the present disclosure can find
application in the treatment of any disease for which delivery
of a therapeutic halogenated stilbene analog or a pharmaceutically acceptable salt, solvate, hydrate, pro drug or metabolite
thereof to a cell or tissue of a subject is believed to be of
therapeutic benefit. Examples of such diseases include hyperproliferative diseases and quiescent malignant diseases. In
particular embodiments, the disease is a hyperproliferative
disease, such as cancer of solid tissues or blood cells. Quiescent malignant diseases that can be treated by a halogenated
stilbene analog of the present disclosure or a pharmaceutically acceptable salt, solvate, hydrate, prodrug or metabolite
thereof include, for example, chronic lymphocytic leukemia.
For example, a compound or composition of a halogenated
stilbene analog of the present disclosure or a pharmaceutically acceptable salt, solvate, hydrate, prodrug or metabolite
thereof can be administered to treat a hyperproliferative disease. The hyperproliferative disease may be cancer, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, pre-neoplastic lesions (such as adenomatous hyperplasia and
prostatic intraepithelial neoplasia), carcinoma in situ, oral
hairy leukoplakia, or psoriasis.
The cancer may be a solid tumor, metastatic cancer, or
non-metastatic cancer. In certain embodiments, the cancer
may originate in the bladder, blood, bone, bone marrow,
brain, breast, colon, esophagus, duodenum, small intestine,
large intestine, colon, rectum, anus, gum, head, kidney, liver,
lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In certain embodiments, the cancer is
ovarian cancer. In particular aspects, the cancer may be a
chemo-resistant cancer, i.e., refractive forms of cancer.
Diseases other than cancer involving altered physiological
status are also encompassed by the present disclosure. For
example, it has been shown that diabetes involves underlying
signaling changes, namely resistance to insulin and failure to
activate downstream signaling through IRS (Burks D J, White
M F. Diabetes 2001 February; 50 Suppl1 :S140-5). Similarly,
cardiovascular disease has been shown to involve hypertrophy of the cardiac cells involving multiple pathways such as
the PKC family (Malhotra A. Mol Cell Biochem 2001 September; 225 (1-):97-107). Inflammatory diseases, such as
rheumatoid arthritis, are known to involve the chemokine
receptors and disrupted downstream signaling (D'Ambrosio
D J Immunol Methods 2003 February; 273 (1-2):3-13).
In another aspect of the disclosure, there is provided a
method for disrupting Wnt signaling in a cell by contacting
the cell with an effective amount of a halogenated stilbene
analog of the disclosure. The Wnt signaling pathway
describes a complex network of proteins most well known for
their roles in embryogenesis and cancer, but also involved in
normal physiological processes in adult animals. The canonical Wnt pathway involves a series of events that occur when
Wnt proteins bind to cell-surface receptors of the Frizzled
family, causing the receptors to activate Dishevelled family
proteins and ultimately resulting in a change in the amount of
~-catenin that reaches the nucleus. Dishevelled (DSH) is a
key component of a membrane-associated Wnt receptor complex which, when activated by Wnt binding, inhibits a second
complex of proteins that includes axin, GSK-3, and the proteinAPC. The axin/GSK -3/APC complex normally promotes
the proteolytic degradation of the .beta-catenin intracellular
signaling molecule. After this ~-catenin destruction complex
is inhibited, a pool of cytoplasmic ~-catenin stabilizes, and
some ~-catenin is able to enter the nucleus and interact with

TCF/LEF family transcription factors to promote specific
gene expression. In this aspect of the disclosure, cells are
brought into contact with an amount of one or more compounds of the disclosure sufficient to disrupt Wnt signaling in
the cells.
Combination Therapy
The active compounds of the present disclosure, i.e., one or
more compounds offormula (I), formula (II) and/or formula
(III) and/or one or more pharmaceutically acceptable salt,
solvate, hydrate, prodrug or metabolite thereof can also be
mixed with other active materials that do not impair the
desired action, or with materials that supplement the desired
action, such as other anticancer agents, and in certain
instances depending upon the desired therapy or target, antibiotics, antifungals, antinflammatories, antiviral compounds
or other agents having a distinct pharmacological effect.
The methods and compositions of the present disclosure
further provide combination therapies which can enhance the
therapeutic or protective effect of the compounds of the
present disclosure, and/or increase the therapeutic effect of
another anti-cancer or anti-hyperproliferative therapy. Therapeutic and prophylactic methods and compositions can be
provided in a combined amount effective to achieve the
desired effect, such as the killing of a cancer cell and/or the
inhibition of cellular hyperproliferation. This process may
involve contacting the cells with, for example, a therapeutic
nucleic acid, such as a chemotherapeutic agent or an inhibitor
of gene expression, as a second therapy. A tissue, tumor, or
cell can be contacted with the compounds or compositions of
the present disclosure and one or more additional anti-cancer
treatment. For example, an additional anticancer treatment
may include a chemotherapeutic agent, an anti-hormonal
agent, radiotherapy, surgical therapy, or immunotherapy.
Examples of chemotherapeutic agents include alkylating
agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including
altretamine, triethylenemelamine, trietylenephosphoramide,
triethiylenethiophosphoramide and trimethylolomelamine;
acetogenins (especially bullatacin and bullatacinone ); a
camptothecin (including the synthetic analogue topotecan);
bryostatin; callystatin; CC-1065 (including its adozelesin,
carzelesin and bizelesin synthetic analogues); cryptophycins
(particularly cryptophycin 1 and cryptophycin 8); dolastatin;
duocarmycin (including the synthetic analogues, KW-2189
and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride,
melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine,
chlorozotocin, fotemustine, lomustine, nimustine, andranimnustine; antibiotics such as the enediyne antibiotics (e.g.,
calicheamicin, especially calicheamicin gmall and calicheamicin omegall; dynemicin, including dynemicinA; bisphosphonates, such as clodronate; an esperamicin; as well as
neocarzinostatin chromophore and related chromoprotein
enediyne antiobiotic chromophores, aclacinomysins, actinomycin, authrarnycin, azaserine, bleomycins, cactinomycin,
carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin,
cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and
deoxy doxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic
acid, nogalarnycin, olivomycins, peplomycin, potfiromycin,
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puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU);
folic acid analogues such as denopterin, methotrexate,
pteropterin, trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine,
carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane,
trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium
acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin;
losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex); razoxane; rhizoxin;
sizofiran; spirogermanium; tenuazonic acid; triaziquone;
2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2
toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolacto!; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., paclitaxel and
doxetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes
such as cisplatin, oxaliplatin and carboplatin; vinblastine;
platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate;
daunomycin; aminopterin; xeloda; ibandronate; irinotecan
(e.g., CPT-I 1); topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoids such as retinoic acid;
capecitabine; cisplatin (CDDP), carboplatin, procarbazine,
mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP 16), tamoxifen, raloxifene,
estrogen receptor binding agents, taxol, paclitaxel, docetaxel,
gemcitabien, navelbine, famesyl-protein tansferase inhibitors, transplatinum, 5-fluorouracil, vincristine, vinblastine
and methotrexate and pharmaceutically acceptable salts,
acids or derivatives of any of the above.
Also included in the formulations may be anti-hormonal
agents that act to regulate or inhibit hormone action on tumors
such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen, raloxifene, droloxifene, A-hydroxytamoxifen, trioxifene, keoxifene, LY1 17018, onapristone, and toremifene; aromatase
inhibitors that inhibit the enzyme aromatase, which regulates
estrogen production in the adrenal glands, such as, for
example, 4(5)-imidazoles, aminoglutethimide, megestrol
acetate, exemestane, formestanie, fadrozole, vorozole, letrozole, and anastrozole; and anti-androgens such as flutamide,
nilutamide, bicalutamide, leuprolide, and goserelin; as well
as troxacitabine (a 1,3-dioxolane nucleoside cytosine analogue); antisense oligonucleotides, particularly those which
inhibit expression of genes in signaling pathways implicated
in abherant cell proliferation, such as, for example, PKCalpha, Raif and H -Ras; ribozymes such as a VEGF expression
inhibitor and a HER2 expression inhibitor; vaccines such as
gene therapy vaccines and pharmaceutically acceptable salts,
acids or derivatives of any of the above.
In an embodiment, a therapeutic formulation or composition set forth herein, which comprises one or more com-

pounds offormula (I), formula (II) and/or formula (III) and/or
one or more pharmaceutically acceptable salt, solvate,
hydrate, prodrug or metabolite thereof, may be administered
before, during, after or in various combinations relative to a
second anti -cancer treatment. The administrations may be in
intervals ranging from concurrently to minutes to days to
weeks. In embodiments where the halogenated stilbene containing composition is provided to a patient separately from
an additional anti-cancer agent, one would generally ensure
that a significant period of time did not expire between the
time of each delivery, such that the two agents would still be
able to exert an advantageously combined effect on the
patient. In such instances, it is contemplated that one may
provide a patient with the inhibitor of gene expression therapy
and the anti-cancer therapy within about 12 to 24 or 72 h of
each other and, more preferably, within about 6-12 h of each
other. In some situations it may be desirable to extend the time
period for treatment significantly where several days (2, 3, 4,
5, 6 or7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between
respective administrations.
Within a single day (24-hour period), the patient may be
given one or multiple administrations of the agent(s). Moreover, after a course of treatment, it is contemplated that there
is a period of time at which no anti -cancer treatment is administered. This time period may last 1, 2, 3, 4, 5, 6, 7 days, and/or
1, 2, 3, 4, 5 weeks, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
months or more, depending on the condition of the patient,
such as their prognosis, strength, health, etc.
Administration of any compound or therapy of the present
disclosure to a patient will follow general protocols for the
administration of such compounds, taking into account the
toxicity, if any, of the agents. Therefore, in some embodiments there is a step of monitoring toxicity that is attributable
to combination therapy. It is expected that the treatment
cycles would be repeated as necessary. It also is contemplated
that various standard therapies, as well as radiation and surgical intervention, may be applied in combination with the
described therapy.
In specific aspects, it is contemplated that a standard
therapy will include chemotherapy, radiotherapy, immunotherapy, surgical therapy or gene therapy and may be
employed in combination with the combination therapy
described herein.
Articles of Manufacture
In another embodiment of the disclosure, an article of
manufacture, or "kit", containing materials useful for the
treatment of the diseases and disorders described above is
provided. In one embodiment, the kit comprises a container
comprising at least one compound of formula (I)-(III), and/or
one or more pharmaceutically acceptable salt, solvate,
hydrate, prodrug or metabolite thereof.
The kit may further comprise a label or package insert on or
associated with the container. The term "package insert" is
used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration,
contraindications and/or warnings concerning the use of such
therapeutic products. Suitable containers include, for
example, bottles, vials, syringes, blister pack, etc. The container may be formed from a variety of materials such as glass
or plastic. The container may hold a compound of formula
(I)-(III) or a formulation thereof which is effective for treating
the condition and may have a sterile access port (for example,
the container may be an intravenous solution bag or a vial
having a stopper pierceable by a hypodermic injection
needle). At least one active agent in the composition is a
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compound of formula (I)-(III). The label or package insert
indicates that the composition is used for treating the condition of choice, such as cancer.
In an embodiment, the kit includes two separate pharmaceutical compositions: one containing a compound of the
present disclosure, and a second pharmaceutical compound.
In another embodiment, an assay or diagnostic kit includes a
labeled compound of the present disclosure and one or more
reagents necessary for detecting the labeled compound upon
binding to its target in-vivo or in-vitro. In a related embodiment, the kit includes a package insert that describes the steps
necessary for carrying out the detection assay.
In another embodiment, a kit of the disclosure further
comprises a needle or syringe, preferably packaged in sterile
form, for injecting the composition, and/or a packaged alcohol pad. Instructions are optionally included for administration of halogenated stilbene compounds by a clinician or by
the patient.
Diagnostic Methods and Diagnostic Probes
Another aspect of the present disclosure provides compounds having general formulas (I)-(III) with a linker moiety
(hydrophobic linkers, hydrophilic linkers, photo-cleveable
linkers, redox reaction-cleveable linkers), wherein the linker
moiety is covalently bonded to a label molecule (a label could
be a fluorophor, biotin, different polymer beads and different
reactive groups). Exemplary biotinylated analogs have been
depicted in FIG. 4 and synthesized according to Example 3,
below.
The compounds of the present disclosure when biotinylated provide suitable means for non-radioactive detection
and quantitation of MAT2A from complex samples, which
offer a useful alternative approach to the routinely used radiometric assays. Therefore, another aspect of the present disclosure relates to the use ofbiotinylated stilbene analogs as a
diagnostic reagent for detecting or monitoring the presence or
levels MAT2A in a complex protein sample. A complex protein sample contains multiple proteins, and may additionally
contain other contaminants. Non-limiting examples of a complex protein sample include tumor tissues, biopsy, serum and
cell extracts.
In one embodiment, the present disclosure relates to a
method of detecting, monitoring or analyzing the levels of
MAT2A in a complex protein sample, said method comprising adding a labeled compound of formula (I)-(III) to said
complex protein mixture under conditions whereby said
labeled compound covalently conjugates to MAT2A; isolating the conjugated MAT2A by a suitable affinity-based separation method, removing unbound proteins, detecting the
level of MAT2A following the separation. In a related
embodiment, the detection can be accomplished by measuring a fluorescence signal emitted from the compound of formula (I)-(III). In another related embodiment, the detection
can be accomplished by measuring a fluorescence signal
emitted from a label bound via a linker to the compound of
formula (1)-(III). The detection step can also be accomplished using various analytical procedures that known to the
artisan for separating and analyzing complex protein mixtures. These analytical procedures include chromatographic
methods such as HPLC, FPLC, ion exchange, size exclusion,
mass spectrometry, and the like.
The linker moiety that can be used to attach a detectable
label to the compounds of the present disclosure can be any of
the linkers shown in FIG. 4. Alternatively, the linker moiety
can a linker moiety comprising a repeating alky leneoxy structure (polyethylene glycols, or "PEG"). Thus, one of skill in

the art can select the linker moiety of the compounds of the
present disclosure in order to provide additional specificity of
them for MAT2A.
Linker moieties include among others, ethers, polyethers,
diamines, ether diamines, poly ether diamines, amides, polyamides, polythioethers, disulfides, silyl ethers, alkyl or alkenyl
chains (straight chain or branched and portions of which may
be cyclic) aryl, diary! or alkyl-aryl groups, having from 0 to 3
sites of aliphatic unsaturation. While normally amino acids
and oligopeptides are not preferred, when used they will
normally employ amino acids of from 2-3 carbon atoms, i.e.
glycine and alanine. Aryl groups in linker moieties can contain one or more heteroatoms (e.g., N, 0 or S atoms). The
number of atoms referred to above are exclusive of hydrogen
in referring to the number of atoms in a group, unless indicated otherwise. The linker moieties, when other than a bond,
will have from about 1 to 60 atoms, usually 1 to 30 atoms,
where the atoms include C, N, 0, S, P, etc., particularly C, N
and 0, and will generally have from about 1 to 12 carbon
atoms and from about 0 to 8, usually 0 to 6 heteroatoms.
In an embodiment, it is desirable to have a detectable label
associated with a compound of the present disclosure to allow
the compound-MAT2A complex to be captured and washed
free of other components of the reaction mixture. The label
will generally be under about 1 kDa. Biotin is a conventional
label or ligand, particularly analogs such as dethiobiotin and
deiminobiotin, which can be readily displaced from streptavidin by biotin. However, any small molecule will suffice that
can be captured and released under convenient conditions.
Affinity purification of biological molecules, for example
proteins, is known in the art and allows the purification of
molecules by exploiting the binding affinity of the target
molecule for a molecular binding partner. Examples of affinity purification methods are fusion tag protein purification,
avidin-biotin system, pull-down assay and the like.
In another embodiment, the present disclosure relates to a
method of diagnosing cancer in a subject, comprising: (1)
contacting a labeled compound of formula (I)-(III) with protein in a complex protein sample obtained from the patient to
bind the compound to and detect MAT2A protein in the
sample; and (2) comparing the level ofMAT2A in the sample
to that in a normal reference sample, whereupon if the level of
MAT2A in the sample is statistically higher than that in the
normal reference sample, a diagnosis of cancer is indicated.
In a related embodiment, the sample is a biopsy sample containing, for example, cancer cells selected from breast, prostate, colorectal, lung, colon, bladder, head and neck, intestine,
ovarian, or skin cancer cells.
In another embodiment, the present disclosure relates to a
method of identifYing a subject who is a candidate for receiving treatment with the compounds of the present disclosure;
such method comprises (1) obtaining a protein sample from
the subject, (2) contacting a detectably labeled compound of
formula (I)-(III) with protein present in a complex protein
sample to bind to and detect MAT2A in said sample; and (3)
comparing the level of MAT2A in the sample to that present
in a normal reference sample, whereupon if the level of
MAT2A in the sample is statistically higher than that in the
normal reference, the subject's candidacy for treatment with
one or more compounds of the present disclosure is indicated.
In a related embodiment, the protein sample is a biopsy
sample, tissue sample, serum sample, urine sample and the
like. If necessary, conventional tools such as protein isolation
kits can be used to obtain protein samples from raw biopsy,
tissue, blood or urine samples. In another related embodiment, the labeled compound is a biotinylated compound of
formula (I)-(III).
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EXAMPLES

chromatographed using 1:10 CH 3 0H:CH 2 Cl 2 to afford 85
mg (43%) of 4a. mp 184-185° C.

The following examples are intended to further illustrate
certain preferred embodiments of the disclosure and are not
limiting in nature. Those skilled in the art will recognize, or be
able to ascertain, using no more than routine experimentation,
numerous equivalents to the specific substances and procedures described herein.
Example 1

Synthesis of(E)-4-Methoxystilbene (4b)
5

Procedure B. Yield 87%. Colorless crystals: mp 136-137°
C.

10

Synthesis of Stilbene Analogs
Materials and Methods:
Chemicals were purchased from Sigma Aldrich, MP Biomedical (4c) or TCI (4d) or were synthesized according to
literature procedures. Solvents were used from commercial
vendors without further purification unless otherwise noted.
Nuclear magnetic resonance spectra were determined using a
Varian instrument (lH, 400 MHz; 13C, 100 MHz unless
otherwise noted). LRMS electron-impact (EI) ionization
mass spectra were recorded at 70 eV on a ThermoFiunigan
PolarisQ (ion trap mass spectrometer). Samples were introduced via a heatable direct probe inlet. High resolution electron impact (EI) ionization mass spectra were recorded at 25
eV on a JEOL 1MS-700T MStation (magnetic sector instrument) at a resolution of greater than 10,000. Samples were
introduced via heatable direct probe inlet. Perfluorokerosene
(pfk) was used to produce reference masses. MALDI mass
spectra were obtained on a Bruker Utraflexstreme time-offlight mass spectrometer (Billerica, Mass.), using DHB (2,5dihydroxybenzoic acid) matrix. Purity of compounds was
>95% as established by combustion analyses. Elemental
analyses were determined by Atlantic Microlabs, Inc., Norcross, Ga. Compounds were chromatographed on preparative
layer Merck silica gel F254 unless otherwise indicated.
General Procedure A.
To 1.5 mmol oftriphenylphosphonium bromide suspended
in 4 mL of anhydrous THF at -78° C. was added 2.25 mmol
(1.5 eq) of n-BuLi (1.6M in hexane). See FIG. 2 for a general
schematic diagram of this reaction. The mixture was allowed
to warm to 25° C. for 30 min, and 2.25 mmol of an aldehyde
in 1 mL of anhydrous THF was added. The mixture was
stirred for 24 h, diluted with CH 2 Cl 2 , washed with saturated
NH4 Cl solution, and dried over anhydrous MgS04 . The product was purified by chromatography and/or recrystallization
as noted for individual stilbenes listed below.
General Procedure B.
Toasolutionof1.5mmolofdiethylphosphonatein4mL
of anhydrous DMF at oo C. was added 2.25 mmol (1.5 eq) of
NaH (washed with hexanes to remove oil). See FIG. 2 for a
general schematic diagram of this reaction. The mixture was
stirred for 20 min, and 1.5 mmol of an aldehyde in 1 mL of
anhydrous DMF was added dropwise. The mixture was
stirred 24 h at 25° C., quenched with ice, extracted with
CH 2 Cl 2 , and dried over anhydrous MgS04 . The product was
purified by chromatography and/or recrystallization as noted
for individual stilbenes listed below.
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Synthesis of (E)-4-(2-Fluorostyryl)-N,N-dimethylaniline (4e)
Procedure B. Yield 84%. Light yellow crystals from acetonitrile. mp 124-126° C. 1 H NMR (acetone-d6 ): o 7.73-7.68
(m, lH), 7.46 (d, 2H, 1=8.8 Hz), 7.26-7.09 (m, 4H), 7.08 (d,
lH, 1=16.8 Hz), 6.75 (d, 2H, 1=9.2 Hz), 2.98 (s, 6H). 13 C
NMR (acetone-d 6 ): o160.18 (d, 1=245.9 Hz), 150.85, 131.67
(d, 1=4.6 Hz), 128.08 (d, 1=8.4 Hz), 127.93 (two C), 126.8 (d,
1=4.5 Hz), 126.14 (d, 1=12.1 Hz), 125.46, 124.59 (d, 1=3.1
Hz), 115.64 (d, 1=22.0 Hz), 115.49 (d, 1=4.6 Hz), 112.44 (two
C), 39.69 (two C). MS: m/z (%) 241 (100), 240 (74), 225 (32),
197 (20), 196 (20), 177 (18), 176 (13). Anal. Calcd for
C 16 H 16FN: C, 79.64; H, 6.68. Found: C, 79.77; H, 6.80.
Synthesis of (E)-4-(3-Fluorostyryl)-N,N-dimethylaniline (4f)
Procedure B. Yield 65%. Light yellow crystals from acetonitrile. mp 147-148° C. 1 H NMR (acetone-d 6 ): o7.42 (d, 2H,
1=8.4 Hz), 7.35-7.25 (m, 3H), 7.17 (d, lH, 1=16.4 Hz), 6.96
(d, lH, 1=16.8Hz), 6.93-6.88 (m, lH), 6.72 (d, 2H, 1=8.8 Hz),
2.95 (s, 6H). 13 C NMR (acetone-d 6 ): o163.47 (d, 1=241.4
Hz), 150.82, 141.36 (d, 1=7.6 Hz), 130.66, 130.42 (d, 1=8.4
Hz), 127.97 (two C), 125.22, 122.63 (d, 1=2.2 Hz), 122.24 (d,
1=2.2 Hz), 113.12 (d, 1=21.3 Hz), 112.43 (two C), 111.96 (d,
1=22.0 Hz), 39.69 (two C). MS: m/z (%) 241 (100), 240 (69),
225 (25), 197 (20), 196 (18), 177 (16), 176 (1 0). Anal. Calcd
for C 16 H 16FN: C, 79.64; H, 6.68. Found: C, 79.86; H, 6.67.
Synthesis of (E)-4-(4-Fluorostyryl)-N,N-dimethylaniline (4g)
Procedure B. Yield 64%. Light yellow crystals from acetonitrile. mp 197-198° C. Anal. CalcdforC 16H 16 FN: C, 79.64;
H, 6.68. Found: C, 79.85; H, 6.64.
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Synthesis of (E)-4-(2-Fluorostyryl)-N,N-diethylaniline (4h)
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Procedure B. Yield 51%. Light yellow crystals from hexane. mp 78-79° C. 1 H NMR (acetone-d 6 ): 07.69-7.65 (m,
lH), 7.40 (d, 2H, 1=8.8 Hz), 7.24-7.08 (m, 4H), 7.04 (d, lH,
1=16.4 Hz), 6.71 (d, 2H, 1=8.8 Hz), 3.42 (q, 4H, 1=7.2 Hz),
1.16 (t, 6H, 1=7.2 Hz). 13 C NMR (acetone-d6 ): o160.13 (d,
1=242.2 Hz), 148.04, 131.73 (d, 1=4.5 Hz), 128.24 (two C),
127.91 (d, 1=7.6 Hz), 126.70 (d, 1=4.5 Hz), 126.27 (d, 1=11.4
Hz), 124.57 (d, 1=3.8 Hz), 124.49, 115.62 (d, 1=22.0 Hz),
114.82 (d, 1=3.8 Hz), 111.76 (two C), 44.19 (two C), 12.21
(two C). MS: m/z (%) 269 (34), 255 (19), 254 (100), 226 (22),
225 (20), 197 (16), 196 (17). Anal. Calcd for C 18H 20 FN: C,
80.26; H, 7.48. Found: C, 80.07; H, 7.61.

Synthesis of (E)-4-Hydroxystilbene (4a)
To 210 mg (1 mmol) of (E)-4-methoxystilbene (4b) in 7
mL ofCH 2 Cl 2 was added 1.28 mL oflM BBr3 (1.3 mmol) in
dichloromethane at -1 oo C. The mixture was stirred for 4 hat
-5° C. and quenched by pouring into cold water. The product
was extracted with CH 2 Cl 2 , dried over anhydrous MgS04 and

Synthesis of (E)-4-(2-Fluorostyryl)-N,N-diphenylaniline (4i)
65

Procedure B. Yield 60%. Light yellow crystals from hexane. mp 114-115° C. 1 H NMR (acetone-d 6 ): 07.77-7.73 (m,
lH), 7.54 (d, 2H, 1=8.4 Hz), 7.34-7.06 (m, 15H), 7.02 (d, 2H,

US 9,132,102 B2
29

30

1=8.8 Hz). 13 C NMR (acetone-d 6 ): o160.39 (d, 1=245.9 Hz),
148.00, 147.73, 131.58, 130.87 (d, 1=4.5 Hz), 129.63, 128.90
(d, 1=8.3 Hz), 127.88, 127.23 (d, 1=3.8 Hz), 125.58 (d, 1=12.0
Hz), 124.75, 124.71, 123.53, 123.25, 118.78 (d, 1=3.8 Hz),
115.76 (d, 1=22.0 Hz). MS: m/z (%) 365 (100), 364 (12), 254
(13).Anal. CalcdforC 26 H 20 FN: C, 85.45; H, 5.52. Found: C,
85.59; H, 5.69.

(78), 243 (25), 214 (16), 195 (16). Anal. Calcd for
C 16 H 15 F 2 N: C, 74.11; H, 5.83. Found: C, 74.01; H, 5.71.

Synthesis of (E)-1-(4-(2-Fluorostyryl)phenyl)-4methylpiperazine (4j)
Procedure B. Yield 65%. Light yellow crystals from acetonitrile. mp 142-144° C. 1 H NMR (acetone-d 6 ): 07.72-7.69
(m, lH), 7.48 (d, 2H, 1=8.8 Hz), 7.28-7.09 (m, 5H), 6.96 (d,
2H, 1=8.8 Hz), 3.22 (t, 4H, 1=5.2 Hz), 2.48 (t, 4H, 1=5.2 Hz),
2.54 (s, 3H). 13 C NMR (acetone-d 6 ): o 160.27 (d, 1=245.2
Hz), 151.59, 131.34 (d, 1=5.3 Hz), 128.42 (d, 1=8.4 Hz),
127.97, 127.81 (two C), 126.98 (d, 1=3.8 Hz), 125.90 (d,
1=12.1 Hz), 126.62 (d, 1=3.8 Hz), 116.85 (d, 1=3.8 Hz),
115.69 (d, 1=22.0 Hz), 115.46 (two C), 55.09 (two C), 48.34
(two C), 45.70. MS: m/z (%) 296 (100), 281 (42), 226 (24),
211 (46), 197 (28), 196 (42), 177 (28). Anal. Calcd for
C 19H 21 FN2 : C, 77.00; H, 7.14. Found: C, 77.22; H, 7.49.
Synthesis of (E)-4-(2-Fluorostyryl)-N,N-dimethylnaphthalen-1-amine (4k)
Procedure B. Yield 18%. Yellow crystals from hexane:
Et2 0. mp 56-58° C. 1 H NMR (acetone-d6 ): o 8.33-8.27 (m,
2H), 8.09 (d, lH, 1=16.4 Hz), 7.95-7.91 (m, lH), 7.80 (d' lH'
1=8.0 Hz), 7.58-7.52 (m, 2H), 7.36-7.15 (m, 4H), 7.28 (d, lH,
1=16.4 Hz), 2.90 (s, 6H). 13 C NMRm (acetone-d6 ): o160.49
(d, 1=246.7 Hz), 151.66, 132.85, 129.41, 129.10 (d, 1=8.4
Hz), 128.92, 128.38 (d, 1=4.6 Hz), 127.67 (d, 1=3.8 Hz),
126.27, 125.78 (d, 1=12.2 Hz), 125.17, 124.92, 124.74 (d,
1=3.0 Hz), 124.25, 124.03, 121.75 (d, 1=3.8 Hz), 115.78 (d,
1=22.0 Hz), 114.19, 44.62. MS: m/z (%) 291 (100), 290 (28),
276 (70), 261 (40), 247 (22), 246 (15). Anal. Calcd for
C 20 H 18FN: C, 82.45; H, 6.23. Found: C, 82.42; H, 6.22.
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Procedure A. Yield 77%. Yellow crystals. mp 146-147° C.
H NMR (acetone-d 6 ): o 7.51-7.46 (m, 3H), 7.28 (d, 1H,
1=16.4 Hz), 7.18-7.12 (m, lH), 7.03 (d, lH, 1=16.4 Hz),
7.00-6.95 (m, lH), 6.76 (d, 2H, 1=8.8 Hz), 2.99 (s, 6H). 13 C
NMR (acetone-d6 ): o 159.28 (dd, 1=236.0 Hz), 156.22 (dd,
1=241.4 Hz), 151.09, 133.04 (d, 1=3.8 Hz), 128.21 (two C),
124.94, 116.97 (dd, 11 =25.5 Hz, 12 =9.6 Hz, two C), 114.08
(dd, 11 =24.7 Hz, 12 =8.7 Hz, two C), 112.38 (two C), 112.12
(d, 1=4.5 Hz), 39.64 (two C). MS: m/z (%) 259 (100), 258
(84), 243 (29), 215 (18), 195 (17). Anal. Calcd for
C 16 H 15 F 2 N: C, 74.11; H, 5.83. Found: C, 74.63; H, 5.90.
Synthesis of (E)-2-(2,6-Difluorostyryl)-N,N -dimethy!aniline (4p)
Procedure B. Yield 92%. Yellow oil. 1 H NMR (acetone-d 6 ):
o7.78 (d, lH, 1=16.8 Hz), 7.65 (dd, lH, 11 =7.6 Hz, 12 =1.6
Hz), 7.36-7.26 (m, 2H), 7.12-7.03 (m, 5H), 2.74 (s, 6H). 13 C
NMR (acetone-d 6 ): o161.06 (dd, 11 =242.2 Hz, 12 =7.6 Hz,
two C), 152.77, 133.81 (t, 1=8.0 Hz), 131.25, 129.19, 128.59
(t, 1=11.0 Hz), 126.72, 122.65, 118.46, 115.31 (t, 1=15.6 Hz),
113.84, 111.92 (dd, 11 =19.4 Hz, 12 =6.8 Hz, two C), 44.31
(two C). MS: m/z (%) 259 (100), 258 (14), 132 (8). Anal.
CalcdforC 16 H 15 F 2 N: C, 74.11; H, 5.83. Found: C, 74.38; H,
5.79.
Synthesis of (E)-3-(2,6-Difluorostyryl)-N,N -dimethylaniline (4q)
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Synthesis of (E)-4-(2,3-Difluorostyryl)-N,N-dimethylaniline (4m)
Procedure A. Yield 88%. Yellow crystals. mp 132-133° C.
H NMR (acetone-d 6 ): o 7.50-7.43 (m, 3H), 7.24 (d, 1H,
1=16.4 Hz), 7.16-7.07 (m, 2H), 7.03 (d, lH, 1=16.4 Hz), 6.73
(d, 2H, 1=8.8 Hz), 2.96 (s, 6H). 13 C NMR (acetone-d 6 ): o
151.09, 151.02 (dd, 11 =243.6 Hz, 12 =12.9 Hz), 147.87 (dd,
11 =246.3 Hz, 12 =12.9 Hz) 133.18 (d, 1=5.3 Hz), 128.19 (two
C), 124.95,124.56 (dd, 11 =7.6 Hz, 12 =4.5 Hz, two C), 121.78
(t, 1=3.0 Hz), 114.65 (d, 1=17.4 Hz), 114.24 (t, 1=3.8 Hz),
112.38 (two C), 39.64 (two C). MS: m/z (%) 259 (100), 258

Synthesis of (E)-4-(2,5-Difluorostyryl)-N,N -dimethy!aniline (4o)
1

40

1

Procedure B. Yield 58%. Yellow crystals from acetonitrile.
mp 139-140° C. 1 HNMR (acetone-d 6 ): 07.78-7.72 (m, lH),
7.44 (d, 2H, 1=8.4 Hz), 7.17 (d, lH, 1=16.4 Hz), 7.04-6.97 (m,
3H), 6.75 (d, 2H, 1=9.2 Hz), 2.98 (s, 6H). 13 C NMR (acetoned 6 ): o 161.65 (dd, 11 =245.2 Hz, 12 =12.1 Hz), 160.00 (dd,
11 =248.6 Hz, 12 =12.1 Hz) 150.87, 131.54 (dd, 11 =4.5 Hz,
12 =2.3 Hz), 127.89 (two C), 125.34,122.84 (dd, 11 =12.1 Hz,
12 =3.8 Hz), 114.56 (t, 1=1.6 Hz), 112.43 (two C), 111.73 (dd,
11 =21.3 Hz, 12 =3.8 Hz, two C), 103.85 (t, 1=26.2 Hz), 39.68
(two C). MS: m/z (%) 259 (100), 258 (71), 243 (30), 215 (15),
195 (14). Anal. Calcd for C 16H 15 F2 N: C, 74.11; H, 5.83.
Found: C, 74.25; H, 5.77.

20

Synthesis of (E)-2-(4-(2-Fluorostyryl)phenyl)-1methyl-lH-imidazole (41)
Procedure B. Yield 47%. Colorless crystals from hexane.
mp 60-61° C. 1 H NMR (acetone-d 6 ): 07.82-7.78 (m, lH),
7.65 (d, lH, 1=16.0 Hz), 7.35-7.29 (m, lH), 7.26 (d, lH,
1=16.0 Hz), 7.22-7.13 (m, 2H), 7.08 (d, lH, 1=1.2 Hz), 6.96
(d, 1H, 1=0.8 Hz), 3.81 (s, 3H). 13 C NMR (acetone-d 6 ): o
160.65 (d, 1=246.7 Hz), 145.39, 129.53 (d, 1=8.3 Hz), 128.89,
127.66 (d, 1=3.0 Hz), 124.98 (d, 1=11.4 Hz), 124.71 (d, 1=3.8
Hz), 122.73 (d, 1=3.8 Hz), 122.18, 116.99 (d, 1=5.3 Hz),
115.83 (d, 1=22.0 Hz), 32.04. MS: m/z (%) 202 (17), 201 (59),
186 (20), 183 (100), 168 (25), 146 (16), 128 (17).Anal. Calcd
forC 12H 11 FN2 : C, 71.27; H, 5.48. Found: C, 71.24; H, 5.61.

Synthesis of (E)-4-(2,4-Difluorostyryl)-N,N -dimethylaniline (4n)

60

Procedure B. Yield 53%. Colorless crystals from hexane.
mp 69-71 o C. 1 H NMR (acetone-d6 ): o 7.38 (d, lH, 1=16.8
Hz), 7.33-7.26 (m, lH), 7.21-7.18 (m, lH), 7.11 (d, lH,
1=17.2 Hz), 7.07-7.00 (m, 2H), 6.93-6.91 (m, 2H), 6.72-6.69
(m, 1H), 2.96 (s, 6H). 13 C NMR (acetone-d 6 ): o161.03 (dd,
11 =248.2 Hz, 12 =7.6 Hz, two C), 151.38, 138.03, 136.83 (t,
1=8.0 Hz), 129.46, 128.70 (t, 1=11.0 Hz), 114.87 (t, 1=16.0
Hz), 114.81, 114.09, 112.98, 111.91 (dd, 11 =19.4 Hz, 12 =6.5
Hz, two C), 111.21,39.93 (two C). MS: m/z (%) 259 (100),
258 (52), 239 (31), 238 (33), 223 (16), 222 (37).Anal. Calcd
forC 16H 15 F 2 N: C, 74.11; H, 5.83. Found: C, 74.30; H, 5.78.
Synthesis of (E)-4-(2,6-Difluorostyryl)-N,N -dimethylaniline (4r)

65

Procedure B. Yield 94%. Pale yellow crystals from hexane.
mp 112-113° C. 1 HNMR (acetone-d 6 ): o7.45 (d, 2H, 1=8.4
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Hz), 7.35 (d, lH, 1=16.8 Hz), 7.27-7.20 (m, lH), 7.01-6.98
(m, 2H), 6.91 (lH, d, 1=16.8 Hz), 6.75 (d, 2H, 1=9.2 Hz), 2.98
(s, 6H). 13 C NMR (acetone-d 6): o160.82 (dd, 11=247.9 Hz,
12 =8.0 Hz, two C), 151.10, 135.99 (t, 1=8.3 Hz), 127.97 (two
C), 127.57 (t, 1=11.3 Hz), 125.41, 115.50 (t, 1=16.0 Hz),
112.40 (two C), 111.79 (dd, 11=19.0 Hz, 12 =6.8 Hz, two C),
109.73,39.65 (two C). MS: m/z (%) 259 (100), 258 (71), 243
(25), 195 (ll).Anal. CalcdforC 16H 15 F2 N: C, 74.11; H, 5.83.
Found: C, 74.08; H, 5.79.

1=8.8 Hz), 7.29 (d, lH, 1=16.8 Hz), 6.91 (t, 2H, 1=8.8 Hz),
6.83 (d, lH, 1=16.8 Hz), 6.75 (d, 2H, 1=8.8 Hz), 2.99 (s, 6H).
13
C NMR (acetone-d6): o160.87 (m, three C), 151.09, 135.59
(m, two C), 127.95 (two C), 125.25, 112.39 (two C), 108.80,
100.65 (dd, 11=30.7 Hz, 12 =25.8 Hz, two C), 39.64 (two C).
MS: m/z (%) 277 (100), 276 (75), 261 (29). Anal. Calcd for
C 16 H 14F3N: C, 69.30; H, 5.09. Found: C, 69.49; H, 4.99.

Synthesis of (E)-4-(2,6-Difluorostyryl)-N,N-diethylaniline (4s)
Procedure B. Yield 57%. Yellow crystals from hexane. mp
70-71° C. 1H NMR (acetone-d 6): o7.43 (d, 2H, 1=8.4 Hz),
7.34 (d, lH, 1=16.8 Hz), 7.27-7.20 (m, lH), 7.01-6.98 (m,
2H), 6.89 (d, lH, 1=16.8 Hz), 6.72 (d, 2H, 1=8.8 Hz), 3.43 (q,
4H, 1=7.2 Hz), 1.16 (t, 6H, 1=7.2 Hz). 13 CNMR(acetone-d6):
o160.80(dd,1 1=247.1 Hz,1 2 =8.0Hz, two C), 148.30,136.07
(t, 1=8.3 Hz), 128.29 (two C), 127.37 (t, 1=10.6 Hz), 124.45,
115.62 (t, 1=16.0 Hz), 111.78 (dd, 11=19.0 Hz, 12 =6.8 Hz, two
C), 111.73 (two C), 109.07, 44.20 (two C), 12.20 (two C).
MS: m/z (%) 287 (44), 272 (1 00), 244 (21 ), 243 (15). Anal.
CalcdforC 18 H 19 F 2 N: C, 75.24; H, 6.66. Found: C, 75.12; H,
6.79.
Synthesis of (E)-4-(3,4-Difluorostyryl)-N,N-dimethylaniline (4t)
Procedure A. Yield 59%. Yellow crystals from hexane. mp
159-160° C. 1HNMR (acetone-d 6): 07.50-7.44 (m, !H), 7.41
(d, 2H, 1=8.8 Hz), 7.32-7.28 (m, lH), 7.27-7.20 (m, lH), 7.11
(d, lH, 1=16.0 Hz), 6.92 (d, lH, 1=16.4 Hz), 6.71 (d, 2H,
1=8.8 Hz), 2.95 (s, 6H). 13 C NMR (acetone-d6): o 150.82,
150.56 (dd, 11=243.9 Hz, 12 =12.9 Hz), 148.99 (dd, 11=244.3
Hz, 12 =12.9 Hz), 130.55 (d, 1=3.0 Hz), 127.91 (two C),
125.16, 122.71 (d, 1=6.1 Hz), 122.68 (d, 1=6.1 Hz), 121.68 (d,
1=2.3 Hz), 117.49 (d, 1=17.4 Hz), 113.96 (d, 1=17.5 Hz),
112.43 (two C), 39.68 (two C). MS: m/z (%) 259 (100), 258
(82), 243 (36), 215 (22), 195 (16). Anal. Calcd for
C 16H 15 F 2 N: C, 74.11; H, 5.83. Found: C, 74.24; H, 5.79.
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Synthesis of (E)-4-(2-chloro-6-fluorostyryl)-N,Ndimethylaniline (4x)
Procedure B. Yield 90%. Yellow crystals, crystals from
hexane. mp 42-44° C. 1H NMR (DMSO-d 6): o7.43 (d, 2H,
1=8.8 Hz), 7.36-7.33 (m, lH), 7.27-7.13 (m, 3H), 6.94 (d, lH,
1=16.8 Hz), 6.73 (d, 2H, 1=8.8 Hz), 2.95 (s, 6H). 13 C NMR
(DMSO-d 6): o 160.74 (d, 1=249.1 Hz), 151.02, 136.87 (d,
1=12.1 Hz), 133.35 (d, 1=6.1 Hz), 128.51 (d, 1=10.1 Hz),
128.31 (two C), 126.28 (d, 1=3.4 Hz), 124.72, 124.59 (d,
1=14.8 Hz), 115.55 (d, 1=23.5 Hz), 113.91 (d, 1=2.1 Hz),
112.58 (two C), 40.30 (two C). MS: m/z (%) 277 (37), 276
(36), 275 (100), 274 (31), 225 (19).Anal. Calcdfor C 16 H 15 Cl
FN: C, 69.69; H, 5.48. Found: C, 69.68; H, 5.61.
Synthesis of (E)-4-(2,6-dichlorostyryl)-N,N-dimethylaniline (4y)
Procedure B. Yield 78%. Yellow crystals from hexane. mp
96-97° C. 1H NMR (acetone-d 6): 7.48-7.44 (m, 4H), 7.257.21 (m, lH), o7.11 (d, lH, 1=16.8 Hz), 6.94 (d, lH, 1=16.4
Hz), 6.77 (d, 2H, 1=8.8 Hz), 2.99 (s, 6H). 13 C NMR (acetoned6): o151.19, 137.63, 135.36, 134.18,128.97 (two C), 128.18
(two C), 128.02 (two C), 124.79, 117.40, 112.41 (two C),
39.68 (two C). MS: m/z (%) 293 (65), 292 (32), 291 (100),
221 (40), 220 (30).Anal. Calcdfor C 16 H 15 Cl 2 N: C, 65.77; H,
5.17. Found: C, 65.52; H, 5.17.
Synthesis of (E)-4-(2,6-Difluorophenethyl)-N,Ndimethylaniline (5r)

40

Synthesis of (E)-4-(3,5-Difluorostyryl)-N,N-dimethylaniline (4u)
Procedure A. Yield 51%. Yellow crystals. mp 136-137° C.
Anal. Calcd for C 16 H 15 F 2 N: C, 74.11; H, 5.83. Found: C,
74.38; H, 5.70.

45

Synthesis of (E)-N,N-Dimethyl-4-(2,3,6-trifluorostyryl)aniline (4v)
Procedure B. Yield 45%. Light yellow crystals from hexane. mp 91-92° C. 1HNMR(acetone-d 6): o7.48 (d, 2H, 1=9.2
Hz), 7.39 (d, lH, 1=16.8 Hz), 7.22-7.14 (m, lH), 7.06-7.00
(m, lH), 6.89 (d, lH, 1=16.8 Hz), 6.76 (d, 2H, 1=8.0 Hz), 3.00
(s, 6H). 13 C NMR (acetone-d 6): o156.09 (ddd, 11=243.9 Hz,
12 =5.3 Hz, 13 =2.4 Hz), 151.31, 147.94 (m, two C), 137.17 (t,
1=8.4 Hz), 128.23 (two C), 124.89, 117.43 (dd, 11=17.1 Hz,
12 =12.1 Hz), 114.02 (dd, 11=19.4 Hz, 12 =10.2 Hz), 112.33
(two C), 111.21 (ddd, 11=25.5 Hz, 12 =7.6 Hz, 13=3.8 Hz),
108.99, 39.59 (two C). MS: m/z (%) 277 (100), 276 (83), 261
(24), 214 (16), 213 (12). Anal. Calcd for C 16H 14F3N: C,
69.30; H, 5.09. Found: C, 69.50; H, 4.97.
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Example 2

60

Synthesis of (E)-N,N-Dimethyl-4-(2,4,6-trifluorostyryl)aniline (4w)
65

Procedure B. Yield 63%. Light yellow crystals from hexane. mp 127-128° C. 1H NMR (acetone-d 6): o 7.45 (d, 2H,

To 150 mg (0.58 mmol) of 4r in 10 mL ofTHF was added
50 mg of 10% Pd-C. The mixture was hydrogenated at 40
psi on a Parr shaker for 5 h. The mixture was filtered through
Celite and chromatographed using 1: 10 EtOAc :hexane to
afford 110 mg (7 6%) of 5r: Colorless crystals from hexane.
mp 42-43° C. 1H NMR (acetone-d 6): o 7.31-7.23 (m, lH),
7.02 (d, 2H, 1=8.4 Hz), 6.98-6.92 (m, 2H), 6.66 (d, 2H, 1=8.4
Hz), 2.90-2.89 (m, 2H), 2.85 (s, 6H), 2.77-2.73 (m, 2H). 13 C
NMR (acetone-d 6): o161.68 (dd, 11=244.1 Hz, 12 =8.7 Hz,
two C), 149.62, 128.98, 128.94 (two C), 128.15 (t, 1=10.3
Hz), 117.36 (t, 1=20.5 Hz), 112.88 (two C), 111.22 (dd,
11=19.4 Hz, 12 =7.2 Hz, two C), 40.10 (two C), 34.73, 24.75.
MS: m/z (%) 261 (40), 134 (100), 118 (27), 91 (22). Anal.
CalcdforC 16 H 17 F 2 N: C, 73.54; H, 6.56. Found: C, 73.53; H,
6.49.

Synthesis of Metabolites of Halogenated Stilbene
Analogs
General Procedure:
To a stirred solution of 4 (0.7 mmol) in CHC1 3 (3 mL) was
added 70% m-CPBA (0.7 mmol, 1 equiv), portionwise at oo
C. The resulting mixture was stirred at room temperature for
5 h. The mixture was diluted with CH 2 Cl 2 (15 mL), washed
with saturated NaHC0 3 solution and water, dried over anhy-
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drous MgS04 and concentrated. The product was purified by
chromatography as noted for individual amine N-oxides
listed below.

Synthesis of (E)-4-(2-chloro-6-fluorostyryl)-N-methylaniline (4dd)

Synthesis of (E)-4-(2,6-difluorostyryl)-N,N-dimethylaniline oxide (4z)
Yield 72%. Rf=0.31 (1:5 CH 3 0H-CH 2 Cl 2 ).mp 100-103°
C. 1 H NMR (DMSO-d 6 ): o8.11 (d, 2H, 1=8.4 Hz), 7.72 (d,
2H, 1=8.8 Hz), 7.43-7.35 (m, 2H), 7.21-7.15 (m, 3H), 3.40 (s,
6H). 13 C NMR (DMSO-d 6 ): o 160.85 (dd, 11 =249.0 Hz,
12 =7.6 Hz, two C), 156.35, 137.30, 134.60 (t, 1=7.6 Hz),
130.13 (t, 1=10.7 Hz), 127.42 (two C), 121.67 (two C),
116.40, 114.44 (t, 1=15.2 Hz), 112.76 (dd, 11 =19.0 Hz, 12 =6.1
Hz, two C), 63.92 (two C). HRMS (EI) Calcd for
C 16H 15 F 2 NO: 275.1121. Found: 275.1120.
Synthesis of (E)-4-(2-chloro-6-fluorostyryl)-N,Ndimethylaniline oxide (4aa)
Yield 54%. Yellow solid. Rf=0.34 (1 :5 CH 3 0H---CH 2 Cl 2 ).
mp 82-84° C. 1 HNMR(acetone-d6 ): o8.21 (d, 2H, 1=8.8 Hz),
7.73 (d, 2H, 1=8.8 Hz), 7.43 (d, lH, 1=16.4 Hz), 7.38-7.32 (m,
3H), 7.26-7.21 (m, 1H),3.50(s, 6H). 13 CNMR(acetone-d 6 ):
o161.29 (d, 1=249.8 Hz), 156.41, 137.41, 135.20 (d, 1=12.1
Hz), 134.40 (d, 1=5.3 Hz), 129.41 (d, 1=10.6 Hz), 126.98 (two
C), 126.06 (d, 1=3.0 Hz), 123.93 (d, 1=14.4 Hz), 121.41 (two
C), 120.31 (d, 1=1.5 Hz), 115.19 (d, 1=23.6 Hz), 63.27 (two
C). HRMS (EI) Calcd for C 16 H 15 ClFNO: 291.0826. Found:
291.0828.
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The procedure used to prepare 4 cc was repeated using 1 g
(3.63 mmol) of 4x and 764 mg (7.26 mmol, 2 equiv) of
cyanogen bromide to afford a product that was purified by
chromatography using 1:5 EtOAc-hexane to afford 400 mg
(42%) of 4dd as a yellow solid: mp 43-45° C. 1 H NMR
(DMSO-d 6 ): 67.37-7.31 (m, 3H), 7.27-7.21 (m, 2H), 7.18 (d,
lH, 1=16.4 Hz), 6.88 (d, lH, 1=16.4 Hz), 6.56 (d, 2H, 1=8.8
Hz), 6.04 (q, lH, 1=5.2 Hz), 2.71 (d, 3H, 1=5.2 Hz). 13 CNMR
(DMSO-d 6 ): o 160.75 (d, 1=248.0 Hz), 150.98, 137.24 (d,
1=12.2 Hz), 133.30 (d, 1=6.1 Hz), 128.49 (two C), 128.33 (d,
1=9.9 Hz), 126.28 (d, 1=3.1 Hz), 124.73 (d, 1=14.5 Hz),
124.40, 115.54 (d, 1=22.9 Hz), 113.12 (d, 1=2.2 Hz), 112.11
(two C), 29.94. MS: m/z (%) 261 (100), 227 (15), 213 (25).
Anal. Calcd for C 15 H 13 Cl FN: C, 68.84; H, 5.01. Found: C,
68.67; H, 5.05.
Synthesis of (E and Z)-4-(2,6-dichlorostyryl)-Nmethylaniline (4ee)
The procedure used to prepare 4 cc was repeated using 1 g
(3.42 mmol) of 4y and 720 mg (6.84 mmol, 2 equiv) of
cyanogen bromide to afford a product that was purified by
chromatography (multiple times and each time using two
developments) using 1:5 EtOAc-hexane to afford 390 mg
(41%) of 4ee as a 9:1 E:Z-mixture of isomers that was a
yellow oil. 1 H NMR (DMSO-d6 ): o 7.49 (d, 2H, 1=8.4 Hz),
7.35 (d, 2H, 1=8.4 Hz), 7.24 (t, lH, 1=8.0 Hz), 6.99 (d, lH,
1=16.4 Hz), 6.82 (d, lH, 1=16.4 Hz), 6.55 (d, 2H, 1=8.4 Hz),
6.01 (q, lH, 1=5.2 Hz), 2.70 (d, 3H, 1=5 02 H 13 C NMR
(DMSO-d 6 ): o150.45, 137.40, 134.69, 133.36, 128.86 (two
C), 128.28, 127.97 (two C), 123.47, 116.09 (two C), 111.57
(two C), 29.50. HRMS (EI) CalcdforC 15 H 13 Cl 2 N: 277.0425.
Found: 277.0425.
2

Synthesis of (E)-4-(2,6-dichlorostyryl)-N,N-dimethylaniline oxide (4bb)
35

Yield 80%. Rf=0.19 (1:10 CH 3 0H---CH 2 Cl 2 ). mp 80-82°
C. 1 H NMR (DMSO-d 6 ): o 8.13 (d, 2H, 1=9.2 Hz), 7.71 (d,
2H, 1=9.2 Hz), 7.55 (d, 2H, 1=8.4 Hz), 7.34 (t, lH, 1=8.0 Hz),
7.22 (d, lH, 1=16.8 Hz), 7.11 (d, lH, 1=16.8 Hz), 3.41 (s, 6H).
13
C NMR (DMSO-d6 ): o 156.31, 136.52, 136.12, 134.51,
134.11, 129.97, 129.34 (two C), 127.24 (two C), 123.85 (two
C), 121.49 (two C), 63.78 (two C). HRMS (EI) Calcd for
C 16H 15 Cl 2 NO: 307.0531. Found: 307.0530.
Synthesis of (E)-4-(2,6-Difluorostyryl)-N-methylaniline (4 cc)
A solution of 1 g (3.86 mmol) of 4r and 820 mg (7.72
mmol, 2 equiv) of cyanogen bromide in 15 mL of acetone was
refluxed for 16 h. The mixture was cooled and concentrated
under a stream of argon. The residue was triturated with ether,
and the combined ethereal extracts were combined and concentrated. The product was refluxed with 25 mL of concentrated HCl for 3 h. The mixture was neutralized with 2M
NaOH solution, extracted with ether, dried over anhydrous
MgSO4 , and concentrated. The product was purified by chromatography using 1:5 EtOAc-hexane to afford 320 mg (34%)
of 4 cc as a yellow solid: mp 51-52° C. 1 H NMR (DMSO-d 6 ):
o 7.32 (d, 2H, 1=8.8 Hz), 7.29-7.21 (m, 2H), 7.14-7.06 (m,
2H), 6.79 (d, lH, 1=16.4 Hz), 6.55 (d, 2H, 1=8.8 Hz), 6.02 (q,
lH, 1=5.2Hz), 2.70 (d, 3H, 1=5.2Hz). 13 CNMR(DMSO-d 6 ):
o160.36 (dd, 11 =246.8 Hz, 12 =8.0 Hz, two C), 150.88, 136.35
(t, 1=7.5 Hz), 128.42 (two C), 127.96 (d, 1=10.7 Hz), 124.53,
115.32 (t, 1=15.5 Hz), 112.33 (dd, 11 =19.1 Hz, 12 =6.8 Hz, two
C), 112.09 (two C), 108.86, 29.93. MS: m/z (%) 246 (30), 245
(100), 244 (15). Anal. Calcd for C 15 H 13 F 2 N: C, 73.45; H,
5.34. Found: C, 73.31; H, 5.26.

).

Synthesis of (E)-4-(2,6-difluorostyryl)-N,N,N-trimethylbenzenaminium iodide (4ff)
40

45

50

To a solution of 200 mg (0.77 mmol) of 4r in acetone (2
mL) was added CH 3 I 328 mg (2.31 mmol, 3 equiv). The
resulting mixture was refluxed for 8 h. The precipitate formed
was collected by filtration, washed with ethyl ester, and the
residual solvent was removed in vacuo to afford 200 mg
(64%) of 4ff as a white solid: mp 198-199° C. 1 H NMR
(DMSO-d 6 ): o7.98 (d, 2H, 1=8.8 Hz), 7.91 (d, 2H, 1=9.2 Hz),
7.47-7.38 (m, 2H), 7.29 (d, lH, 1=16.8 Hz), 7.23-7.17 (m,
2H), 3.62 (s, 9H). 13 C NMR (DMSO-d6 ): o 160.30 (dd,
11 =249.1 Hz, 12 =7.4 Hz, two C), 146.72, 138.44, 133.04 (t,
1=7.8 Hz), 130.00 (t, 1=10.8 Hz), 128.05 (two C), 121.03 (two
C), 117.44, 113.58 (t, 1=15.5 Hz), 112.23 (dd, 11 =19.2 Hz,
12 =5.7 Hz, two C), 56.45 (three C). Anal. Calcd for
C 17 H 18F 21 N: C, 50.89; H, 4.52. Found: C, 51.10; H, 4.49.

55

Example 3
Synthesis ofBiotinylatedAnalogs of Halogenated
Stilbenes
60

65

In this example, several biologically active biotin-labeled
halogenated stilbene analogs, in particular fluorinated N,Ndialkylaminostilbenes (FIDAS or FIDAS agents), where prepared. As shown in FIG. 4, several Biotin-FIDAS compounds
with variable spacers between the FIDAS agent and the biotin
were prepared. It was established, through the synthesis of
other amides lacking the biotin heterocycle or possessing
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biotin alone, that activity resides in the stilbene and not in the
biotin portion of these molecules. The optimal spacer length
between the two termini was determined, and the binding and
eluting conditions for Biotin-FIDAS and streptavidin beads
were established.

7.37 (d, lH, 1=16.8 Hz), 7.23-7.17 (m, 2H). 13 C NMR
(DMSO-d 6 ): o 160.79 (dd, 11 =249.4 Hz, 12 =7.3 Hz, two C),
147.27, 143.81, 133.35 (t, 1=7.9 Hz), 130.82 (t, 1=10.7 Hz),
128.21 (two C), 124.46 (two C), 119.70 (t, 1=1.6 Hz), 113.79
(t, 1=15.1 Hz), 112.65 (dd, 11 =19.5 Hz, 12 =5.9 Hz, two C).
MS: m/z (%) 261 (61), 231 (67), 214 (45), 194 (34), 183
(100).Anal. CalcdforC 14H9 F2 NO: C, 64.37; H, 3.47. Found:
C, 64.56; H, 3.42.

5

Synthesis of (E)-4-(2,6-Difluorostyryl)-N,N-dimethyl-3-nitroaniline (6)
To a solution of 1.63 g (6.18 mmol, 1.2 equiv) of diethyl
2,6-difluorobenzylphosphonate in 15 mL of anhydrous DMF
at oo C. was added 310 mg (7.72 mmol, 1.5 equiv) of 60%
NaH. The mixture was stirred for 30 min, and a solution ofl.O
g (5.15 mmol) of 4-(dimethylamino)-3-nitrobenzaldehyde in
8 mL of anhydrous DMF was added over a 10 min period. The
mixture was stirred for 2 hat oo C. and poured into cold water.
The precipitate was collected by filtration and recrystallized
from acetonitrile to afford 1.1 g (70%) of 6 as red crystals: mp
152-153° C. 1 H NMR (acetone-d 6 ): o7.81 (d, 1H, 1=8.8 Hz),
7.68 (d, lH, 1=16.4 Hz), 7.38-7.30 (m, lH), 7.17 (d, lH, 1=3.2
Hz), 7.10-7.03 (m, 3H), 7.01 (d, lH, 1=16.8 Hz), 3.1 (s, 6H).
13
C NMR (acetone-d 6 ): o 160.76 (dd, 11 =248.3 Hz, 12 =7.5
Hz, two C), 150.56, 150.03, 129.66 (t, 1=8.7 Hz), 128.73 (t,
1=10.7 Hz), 128.08, 118.20, 116.16, 114.92 (t, 1=1.6 Hz),
114.52 (t, 1=15.1 Hz), 111.74 (dd, 11 =19.7 Hz, 12 =6.5 Hz, two
C), 106.01, 39.31 (two C). HRMS (EI) Calcd for
C 16H 14F 2 N 2 0 2 : 304.1023. Found: 304.1016.
Synthesis of (E)-4-(2,6-Difluorostyryl)-W ,W -dimethylbenzene-1,3-diamine (7)
A solution of5 g (26.4 mmol, 8.5 equiv) ofSnC1 2 in 7 mL
of cone HCl was added dropwise to a solution of0.95 g (3.1
mmol) of 6 in 100 mL of glacial acetic acid. The mixture was
stirred for ca. 12 hat 25° C. A precipitate was collected by
filtration, washed with 5 mL of glacial acetic acid, and suspended in 200 mL of water. The aqueous suspension was
adjusted to pH 9-1° with NaOH and was extracted with Et2 0.
The combined ethereal extracts were washed with water,
dried over anhydrous MgS04 and concentrated. The residue
was recrystallized from ethanol to afford 590 mg (69%) of7
as yellow crystals: mp 97-98° C. 1 H NMR (DMSO-d6 ): o7.41
(d, lH, 1=16.4 Hz), 7.27 (d, lH, 1=8.8 Hz), 7.24-7.18 (m, lH),
7.12-7.05 (m, 2H), 6.61 (d, lH, 1=16.4 Hz), 6.10 (dd, lH,
11 =8.8 Hz, 12 =2.4 Hz), 6.03 (d, lH, 1=2.8 Hz), 5.05 (br.s, 2H),
2.87 (s, 6H). 13 C NMR (DMSO-d 6 ): o 160.25 (dd, 11 =246.0
Hz, 12 =7.9 Hz, two C), 151.95, 147.98, 132.39 (t, 1=7.1 Hz),
127.45 (t, 1=11.1 Hz), 127.06, 116.11 (t, 1=15.1 Hz), 112.20
(dd, 11 =18.7 Hz, 12 =6.8 Hz, two C), 111.39, 108.21, 103.52,
99.07, 40.28 (two C). MS: m/z (%) 275 (21), 274 (100), 273
(33), 257 (15), 211 (16). Anal. Calcd for C 16H 16F 2 N 2 : C,
70.06; H, 5.88. Found: C, 70.18; H, 5.94.
Synthesis of (E)-1 ,3-Difluoro-2-(4-nitrostyryl)benzene (8)
To a solution of 956 mg (2 mmol) of (4-nitrobenzyl)triphenylphosphonium bromide and 284 mg (2 mmol) of 2,6difluorobenzaldehyde in 20 mL ofCH 2 Cl 2 was added 5 mL of
0.48 M NaOH solution (2.4 mmol, 1.2 equiv) dropwise over
a 10 min period. The red solution was heated at 50° C. for 1 h.
The organic layer was separated, washed with a saturated
aqueous NaHS0 3 solution and water, and dried over anhydrous MgS04 . The residue was recrystallized from ethanol to
afford 360 mg (69%) of 8 as light yellow crystals: mp 136137° C. 1 H NMR (DMSO-d 6 ): o8.23 (d, 2H, 1=8.8 Hz), 7.93
(d, 2H, 1=8.8 Hz), 7.50 (d, lH, 1=16.8 Hz), 7.46-7.40 (m, lH),

Synthesis of (E)-4-(2,6-Difluorostyryl)aniline (9)
10

15

20

25

3

°

The procedure described for the preparation of 7 was
repeated using 300 mg (1.15 mmol) of 8 in 20 mL of glacial
HOAc and 1.85 g (9.76 mmol, 8.5 equiv) ofSnC1 2 in 3 mL of
cone HCl to afford, after stirring ca. 12 h at 25° C. and
quenching with water, a precipitate. The precipitate was collected by filtration, washed with 5 mL of glacial acetic acid
and suspended in 80 mL of water. The aqueous suspension
was adjusted to pH 9-10 with NaOH and was extracted with
Et2 0. The combined ethereal extracts were washed with
water, dried over anhydrous MgS0 4 , and concentrated. The
product was recrystallized from hexane to afford 220 mg
(83%) of 9 as colorless crystals: mp 74-75° C. 1 H NMR
(DMSO-d 6 ): o 7.28 (d, 2H, 1=8.8 Hz), 7.27-7.22 (m, lH),
7.21 (d, lH, 1=16.8 Hz), 7.13-7.06 (m, 2H), 6.77 (d, lH,
1=16.8 Hz), 6.57 (d, 2H, 1=8.8 Hz), 5.43 (s, 2H). 13 C NMR
(DMSO-d 6 ): o 160.35 (dd, 11 =246.8 Hz, 12 =8.0 Hz, two C),
150.06, 136.41 (t, 1=7.9 Hz), 128.42 (two C), 127.99 (t,
1=10.3 Hz), 124.68, 115.31 (t, 1=15.1 Hz), 114.29 (two C),
112.33 (dd, 11 =19.1 Hz, 12 =6.3 Hz, two C), 108.84. MS: m/z
(%) 232 (18), 231 (100), 183 (13). Anal. Calcd for
C 14H 11 F 2 N: C, 72.72; H, 4.79. Found: C, 72.77; H, 4.83.
Synthesis of (E)-N-(2-(2,6-Difluorostyryl)-5-(dimethylamino )phenyl)-5-(2-oxohexahydro-1 H -thieno
[3,4-d]imidazol-4-yl)pentanamide (1 0)

35

40
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50
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60

To 200 mg (0.82 mmol) of biotin was added 8 mL (0.11
mol) of SOC1 2 . The mixture was stirred for 1 hat 25° C. The
mixture was concentrated and co-evaporated with benzene
(two 15 mL portions) to give the acid chloride. To a solution
of186 mg (0.68 mmol) of7 and 83 mg (0.82 mmol, 1.2 equiv)
of Et 3 N in 5 mL of anhydrous THF was added the acid
chloride in 8 mL of anhydrous THF dropwise. The mixture
was stirred for 2 hat 25° C., poured into water and extracted
with CH 2 Cl 2 . The combined organic phases were dried over
anhydrous MgSO4 and evaporated to give a product that was
purified by chromatography using 1:10 CH 3 0H-CH 2 Cl 2 to
afford 200 mg (59%) of 10 as a yellow solid: mp 183-184° C.
1
H NMR (DMSO-d 6 ): o9.51 (s, lH), 7.61 (d, lH, 1=8.8 Hz),
7.40 (d, lH, 1=16.4 Hz), 7.32-7.24 (m, lH), 7.15-7.09 (m,
2H), 6.80 (d, lH, 1=16.8 Hz), 6.67-6.61 (m, 2H), 6.45 (s, lH),
6.36 (s, lH), 4.31-4.28 (m, lH), 4.15-4.11 (m, lH), 3.12-3.07
(m, lH), 2.93 (s, 6H), 2.80 (dd, lH, 11 =12.4 Hz, 12 =5.2 Hz),
2.57 (d, lH, 1=12.4 Hz), 2.31 (t, 2H, 1=7.2 Hz), 1.69-1.35 (m,
6H). 13 C NMR (DMSO-d 6 ): o 171.90, 163.14, 160.40 (dd,
11 =247.6 Hz, 12 =7.9 Hz, two C), 151.03, 137.35, 132.05 (t,
1=8.0 Hz), 128.27 (t, 1=11.0 Hz), 126.36, 120.44, 115.40 (t,
1=15.0 Hz), 112.36 (dd, 11 =19.1 Hz, 12 =6.4 Hz, two C),
110.93, 110.65, 110.20, 61.47, 59.64, 55.86, 40.40 (two C),
40.31, 36.11, 28.70, 28.55, 25.84. HRMS (EI) Calcd for
C 26 H30 F 2 N4 0 2 S: 500.2057. Found: 500.2047.
Synthesis of (E)-N-(4-(2,6-Difluorostyryl)phenyl)-5(2-oxohexahydro-1 H-thieno [3,4-d]imidazol-4-yl)
pentanamide (11)

65

To a suspensionoflOOmg (0.41 mmol1 equiv) ofbiotinin
3 mL of anhydrous DMF was added 66 mg (0.49 mmol, 1.2
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equiv) of 1-hydroxybenzotriazole hydrate, 94 mg (0.49
mmol, 1.2 equiv) of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, and 79 mg (0.78 mmol, 1.9
equiv) ofEt3 N. The mixture was stirred for 10min, and95 mg
(0.41 mmol) of9 was added. The mixture was stirred for 24 h
at 25° C. and poured into water. The precipitate was collected
by filtration and chromatographed using 1:1 EtOAc-MeOH
to give 120 mg (66%) of11 as white crystals: mp 278-280° C.
1
HNMR(DMSO-d 6): o9.99 (s, lH), 7.64 (d, 2H, 1=8.8 Hz),
7.56 (d, 2H, 1=8.8 Hz), 7.37-7.29 (m, 2H), 7.19-7.12 (m, 2H),
7.02 (d, lH, 1=16.4 Hz), 6.44 (s, lH), 6.36 (s, lH), 4.33-4.29
(m, lH), 4.16-4.13 (m, lH), 3.15-3.10 (m, lH), 2.83 (dd, lH,
11 =12.8 Hz, 12 =4.8 Hz), 2.58 (d, lH, 1=12.0 Hz), 2.33 (t, 2H,
1=7.2 Hz), 1.70-1.33 (m, 6H). 13 C NMR (DMSO-d 6): o
171.70, 163.13, 160.53 (dd, 11 =247.8 Hz, 12 =7.7 Hz, two C),
140.09, 135.28 (t, 1=7.9 Hz), 131.77, 129.18 (t, 1=10.7 Hz),
127.69 (two C), 119.54 (two C), 114.61 (t, 1=15.5 Hz),
113.25, 112.45 (dd, 11 =19.1 Hz, 12 =6.3 Hz, two C), 61.48,
59.63, 55.82, 40.28, 36.70, 28.67, 28.53, 25.50. HRMS (EI)
Calcd for C 24H 25 F 2 N 3 0 2 S: 457.1636. Found: 457.1650.
Anal. Calcd for C 24 H 25 F 2 N 3 0 2 S: C, 63.00; H, 5.51. Found:
C, 62.82; H, 5.47.

4.34-4.29 (m, lH), 3.97 (s, 2H), 3.59-3.45 (m, 8H), 4.42-3.29
(m, 4H), 3.23-3.17 (m, lH), 3.13 (s, 3H), 2.92 (dd, lH,
11 =12.4 Hz, 12 =4.8 Hz), 2.69 (d, lH, 1=12.4 Hz), 2.18 (t, 2H,
1=7.2 Hz) 1.81-1.39 (m, 6H). It was noted that the MALDITOFMS Calcd for C 33 H44 F 2 N 5 0 5 S [MH+]: 660.3030.
Found 660.3040.

5

Example 4
10

Natural Stilbene Analogues Resveratrol and
Pterostilbene Inhibit Wnt Signaling

Materials and Methods:
The following materials and methods have been used to
15 generate the results in this and other examples in the application.
Cell Culture and Transfection.
HEK293T, HCT116 and SW480 cells were grown in
DMEM medium (Mediatech) supplemented with 10% fetal
20 bovine serum and 1% penicillin/streptomycin. LS 174 T cells
were grown in RPMI medium (Mediatech) supplemented
with 5% fetal bovine serum and 1% penicillin/streptomycin.
HEK293T cells were transiently transfected using the calcium phosphate method as described in Zhang, W. eta!., Mol
Synthesis of (E)-N-(4-(2,6-Difluorostyryl)phenyl)25 Cell Biol2006, 26, 2055-2064 (incorporated herein by referN -methyl-5-(2-oxohexahydro-1 H -thieno[3,4-d]imience).
dazol-4-yl)pentanamide (12)
Western Blot.
Western blots were performed using the following antibodThe procedure used to prepare 10 was repeated using 167
ies: ~-catenin (Sigma, C2206), c-Myc (Epitomics, 1472-1),
mg (0.68 mmol) of 4 cc and 200 mg (0.82 mmol, 1.2 equiv) of
biotin to afford a product that was purified by chromatogra- 30 Axin2 (Cell Signaling, 2151), ~-Actin (Sigma, A1978),
TCF 4 (Epitomics, 2114-1) and pygopus2 (Santa Cruz,
phy using 1:10 CH 3 0H-CH 2 Cl 2 to afford 130 mg (41%) of
sc-74878), Cyclin D1 (Cell signaling, 2926).
12 as a colorless solid: mp 91-93° C. 1 HNMR (DMSO-d6): o
RT-PCR.
7.71 (d, 2H, 1=8.0 Hz), 7.41-7.36 (m, 2H), 7.33 (d, 2H, 1=8.4
LS174 cells were treated with DMSO or Wnt inhibitors.
Hz), 7.21-7.14 (m, 3H), 6.38 (s, lH), 6.33 (s, lH), 4.30-4.26
(m, lH), 4.09-4.06 (m, lH), 3.17 (s, 3H), 3.05-3.00 (m, lH), 35 After 36 h, RNA was isolated using the RNeasy kit (Qiagen).
RT-PCR was performed as described in Zhang et tal., Mol
2.80 (dd, lH, 11 =12.2 Hz, 12 =5.2 Hz), 2.56 (d, lH, 1=12.4
Cell Biol 2006, 26, 2055-2064. The following primers were
Hz), 2.09 (br.s, 2H), 1.58-1.18 (m, 6H). 13 C NMR (DMSOused: ~-actin: 5'-CAACCGCGAGAAGATGAC-3' (SEQ ID
d6): o171.96, 163.13, 160.61 (dd, 11 =248.0 Hz, 12 =7.6 Hz,
N0:01), 5'-AGGAAGGCTGGAAGAGTG-3' (SEQ ID
two C), 144.40, 134.71 (t, 1=7.9 Hz), 129.80 (t, 1=11.1 Hz),
128.27 (two C), 128.07, 128.01, 115.70 (two C), 114.35 (t, 40 N0:02); surivivin: 5'-CATTCGTCCGGTTGCGCTTTCC-3'
(SEQ ID N0:03), 5'-GCGCACTTTCTCCGCAGTTTCC-3'
1=15.1 Hz), 112.54 (dd, 11 =19.1 Hz, 12 =6.4 Hz, two C),
(SEQ ID N0:04); c-Myc: 5'-TGGGCTGTGAGGAG61.42, 59.62, 55.75, 40.27, 37.20, 33.64, 28.54, 28.43, 25.32.
GTTTG-3' (SEQ ID N0:05), 5'-TATGTGGAGCGGCTMALDI-TOFMS Calcd for C 25 H 28 F 2 N 3 0 2 S [MH+]:
TCTCG-3' (SEQ ID N0:06); Axin2: 5'-CACCACCACCAC472.1870. Found 472.1872.
45 CACCATTC-3'
(SEQ
ID
N0:07),
5'-GCATCCACTGCCAGACATCC-3' (SEQ ID N0:08);
Synthesis of N -(2-(4-(2,6-Difluorostyryl)phenyl)-4oxo-8, 11-dioxa-2,5-diazamidecan-13-yl)-5-(2-oxoTCF4: 5'-CACCACATCATACGCTACAC-3' (SEQ ID
hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanaN0:09), 5'-CGACCTTTGCTCTCATTTCC-3' (SEQ ID
mide (13)
NO: 10); pygopus2: 5'-GGCCGGTCTGCAAATGAAG-3'
so (SEQ ID NO: 11 ), 5'-TCCACCTCCAGTGCTGTAG-3' (SEQ
To a solution of34 mg (0.14 mmol, 1.5 equiv) of 4 cc in 1
ID N0:12); Lgr5: 5'-CCTGCTTGACTTTGAGGAAGAC-3'
mL of absolute ethanol was added 50 mg (0.092 mmol) of
(SEQ ID N0:13), 5'-ATGTTCACTGCTGCGATGAC-3'
(SEQ ID N0:14); CD44: 5'-CAGAATGGCTGAT( +)-biotinyl-iodoacetamidyl-3,6-dioxaoctanediamine and 20
CATCTTG-3' (SEQ ID NO: 15), 5'-CAAATGCACCATTTCmg (0.14mmol, 1.5 equiv) ofanhydrousK2 COy The mixture
was refluxed for 12 h, filtered, and concentrated. The product ss CTGAG-3' (SEQ ID N0:16); Ki67: 5'-ACAGAGTGCTwas chromatographed using 1:10 CH 3 0H-CH 2 Cl 2 to afford
CAACAACTTC-3'
(SEQ
ID
NO: 17),
5'-GCTTGCAGAGCATTTATCAG-3' (SEQ ID NO: 18).
16 mg (26%) of 13 as a clear glass that resisted crystallization.
The initial product isolated was the pure (E)-isomer but durLuciferase and Cell Proliferation Assay.
ing concentration, even at low temperature, rapidly equiliHEK293T cells were transiently transfected in a 12-well
brated to a mixture of (E/Z)-isomers. The ratio of isomers 60 plate with 0.2 flg of the Super8xTOPFlash reporter and 0.05
varied with solvent ranging from ca. 10:90 in acetone-d 6 to
flg of Renilla luciferase reporter. Culture medium was
changed after 12 h. After 6 h, cells were treated with DMSO
60:40 in DMSO-d 6. This isomerization necessarily complicated the NMR spectra, and the data reported below is for the
or Wnt inhibitors for 12 h, and then treated with 25 mM LiCl
principal (E)-isomer: 1 H NMR (acetone-d 6): 7.48 (d, 2H,
or Wnt conditioned medium. After 12 h, cells were harvested
1=8.8 Hz), 7.42-7.35 (m, 2H), 7.30-7.22 (m, lH), 7.13 (br.s, 65 and luciferase activity measured by Dual-luciferase Reporter
Assay System (Promega, Madison Wis.). All conditions were
lH), 7.05-7.00 (m, 2H), 6.95 (d, lH, 1=16.8 Hz), 6.75 (d, 2H,
done in triplicate and each experiment was carried out at least
1=9.2 Hz), 5.87 (s, lH), 5.64 (s, lH), 4.51-4.46 (m, lH),
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two times. For cell proliferation assay, CRC cells were treated
with DMSO or inhibitors for 2 d and 4 d. The cell numbers
and viability were analyzed by Vi-Cell Cell Viability Analyzer.
Tumor Xenograft in Nude Mice.
LS174 or HT29 colon cancer cells (2x10 6 ) were injected
subcutaneously into both flanks of 6-8 week C57BL/6J athymic nude mice as described in Zhang et a!., Mol Cell Biol
2006, 26, 2055-2064. Compound 4r or 4dd was dissolved in
corn oil or PEG400. The mice were treated with 20 mg/kg/day
of 4r by ip injection or gavage (50 fll/mouse). Control mice
were treated with same volume of corn oil or PEG400. The
body weight and tumor growth were analyzed twice weekly
for one month. Tumor size was measured using digital caliper.
The tumor volume was calculated by the formula: V= 1/2LW2
(mm3).
Immunofluorescence.
Cells grown on cover glass were fixed by 4% paraformaldehyde for 20 min at room temperature. The cells were permeabilized with PBS containing 0.3% (w/v) Triton X-100
and blocked by 5% normal goat serum in PBS for 30 min
Anti-~-catenin antibody (1:300, Sigma, St. Louis, Mo.) was
diluted in blocking solution and incubated with cells overnight. The cells were washed 3 times with PBS and further
incubated with Alexa-488-labeled anti-rabbit IgG (1:500)
diluted in PBS for 40 min. The cover glasses were washed,
mounted on glass slides, viewed and photographed with an
Olympus FW1000 confocal microscope. Cells grown on
cover glass were treated with fluorescent compounds for 2 h,
6 h, 12 hand24 hrespectively. Treated cells were fixed by 4%
paraformaldehyde for 20 min at room temperature. Then cells
were washed 3 times with PBS and mounted on glass slides,
viewed under the fluorescence of 405 urn-wavelength and
photographed with an Olympus FW1000 confocal microscope.
To identifY Wnt pathway inhibitors for CRC prevention
and treatment, a number of anti-cancer agents from plants
were screened using the TopFlash reporter assay. The TopFlash reporter was transfected into HEK293T cells, and the
cells were treated with Wnt3A-conditioned medium in order
to activate the luciferase reporter. Resveratrol (100 f.LM) significantly inhibited Wnt-induced luciferase activity. To determine ifresveratrol regulates ~-catenin degradation, the cells
were treated with 25 mM LiCl, which inhibits GSK-3 and
stabilizes ~-catenin. In this assay, LiCl activated the reporter
more strongly than W nt3A conditioned medium. Resveratrol
strongly inhibited LiCl-induced Wnt signaling, suggesting
that resveratrol inhibits Wnt signaling by regulating ~ -catenin
activity, but not its degradation. Emodin is an anti-cancer
agent from plants; it exists in many unpurified resveratrol
products. Emodin had no effect on Wnt signaling. See Zhang
eta!., J. ofMed. Chern. 54, 1288-1297 (2011).
To confirm these results, ~-catenin target genes were analyzed in LS174 CRC cells by Western blot and RT-PCR. The
protein levels of c-Myc and Cyclin D1, which are ~-catenin
targets, are reduced by resveratrol but not its isomer, cis- or
(Z)-resveratrol. Cyclin B1 levels were decreased, whereas
p21 WAFliCIPl levels increased, consistent with the fact that
p21 WAFliCIPl expression is repressed by c-Myc. ~-catenin
levels were not affected by resveratrol. Next, the mRNA
levels of~-catenin target genes were analyzed using RT-PCR.
Expression of survivin, Lgr5, CD44, and c-Myc were
decreased in resveratrol-treated cells. The cell proliferation
marker, Ki67, also decreased. These results confirmed that
resveratrol inhibits endogenous Wnt target genes in CRC
cells.

Many stilbene derivatives also exhibit anti-cancer activity.
To determine the structure/activity relationship of these compounds, several resveratrol analogs were tested. It was found
that pterostilbene inhibits Wnt signaling. To determine the
effects of resveratrol and pterostilbene on cell growth, LS 17 4
CRC cells were treated with resveratrol and pterostilbene for
2 d and 4 d. Both compounds inhibited cell proliferation.
Similar results were observed with other CRC lines Pterostilbene was more active than resveratrol in these assays, suggesting that an assay involving Western blots to measure Wnt
target protein level was effective to identifY other resveratrol
analogs for Wnt inhibition and CRC repression.

5

10

Example 5
15

Halogenated Stilbene Analogs are Potent Wnt
Inhibitors
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A panel of stilbene analogs was designed and synthesized
(FIGS. 2, 3, SA and 6A). Various monosubstituted hydroxyl,
alkoxy, amino and N,N -dialkylaminostilbenes were analyzed
using the Western blot assay (FIG. SB, SC), and of these
substituents, (E)-4-styryl-N,N-dimethylaniline (4d) at 30 f.LM
with an N,N-dimethylamino substituent strongly repressed
Wnt target genes, Axin2 and c-Myc, in CRC cells (FIG. SC).
However, the solubility of 4d was poor and it was not effective
below 10 f.LM concentrations (data not shown). To improve its
solubility and activity, compound 4d was modified with
2'-fluoro 4e, 3'-fluoro 4f and 4'-fluoro 4g substituents (FIG.
SD). Both compounds 4e and 4fhad good activity at 10 f.LM,
(E)-4-(2-fluorostyryl)-N,N-dimethylaniline. Compound (4e)
was best among all of the monofluoro-substituted compounds. Modifications of the N,N-dimethylamino group
within compound 4e were also analyzed, and it was found that
the N,N-diethylamino group in (E)-4-(2-fluorostyryl)-N,Ndiethylaniline (4h) is also active at 10 f.LM, but not as potent as
compound 4e and the N,N-diphenylamino group in compound 4i was inactive (FIG. SE). These analogs had no effect
on ~-catenin levels, further indicating that they affect ~-catenin activity, but not its stability. The effects of compound 4e,
resveratrol, and pterostilbene on CRC cell growth were compared and it was found that 4e is a significantly better inhibitor
in the cell proliferation assay (FIG. SF).
Based on the improved activity seen in compound 4e relative to compound 4d, dihalogenated N,N-dimethylaminostilbenes in which at least one of the fluorine substituents is in the
2'- or 3'-position were synthesized (FIG. 6A). The compounds with a 2'-flu oro and another fluoro ortho or meta to the
double bond (compounds 4m, 4o and 4r) are more active than
compound 4e (FIG. 6B). The (E)-4-(2,6-difluorostyryl)-N,Ndimethylaniline (compound 4r) had the best activity. The
ortho- and meta-N,N-dimethylamino analogs of compound
4r (i.e., compounds 4p and 4q) are not as active as compound
4r, indicating that the para-dimethylamino in compound 4r is
important for its activity (FIG. 6C). Based on the structure of
compound 4r, two trihalogenated dimethylaminostilbenes
were synthesized (compounds 4v and 4w) in which two of the
fluorine substituents are in the 2'- and 6'-positions (FIG. 6D).
Although compounds 4v and 4w were active at 10 f.LM, they
showed no significant improvements over compound 4r.
When the stilbene carbon-carbon double bond in compound
4r was reduced to a saturated, single bond in the 1,2-diarylethane compound 5r, the activity was lost, suggesting that the
double bond is essential for biological activity (FIG. 6D).
LS174 CRC cells were treated with different dosages of compound 4r and it was found that compound 4r significantly
inhibited Wnt target genes at 2.5 f.LM and was even active at
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0.5 f.LM(FIG. 6E). For example, based on the Western blot and
cell proliferation assays, it was determined that stilbene 4r
was 10- to 100-fold more potent than resveratrol and pterostilbene.

CRC cells (FIG. SC). RT-PCR assay suggested that compound 4r strongly inhibited the transcription of Wnt target
genes. It also inhibited TCF4 genes, but had no significant
effects on pygopus2 genes, which suggests that these halogenated stilbene analogs inhibit Wnt/mediated transcription at
multiple levels (FIG. SD).

5

Example 6

Example 8

Halogenated Stilbene Analogs Inhibit CRC In Vitro
and In Vivo
10

In this example, the effects of the stilbene analogs of the
present disclosure on CRC cells growth was analyzed. Consistent with the Western blot results, stilbene compound 4r
was more potent than compound 4e in the cell proliferation
assay; it inhibited LS 174 cell proliferation at nanomolar
concentrations (FIG. 7A). To test the effects of compound 4r
on tumor growth in vivo, LS174 cells were injected subcutaneously into the flanks of athymic nude mice, which had been
randomized into two groups. One group of mice was treated
with compound 4r (20 mg/kg/day) dissolved in corn oil by
intraperitoneal (ip) injection. The control mice were treated
with the same volume of com oil (50 f.LL) by ip injection. The
mice were weighted and tumors measured twice weekly. The
compound 4rtreated mice and control mice had no significant
difference in body weight within one month (FIGS. 7B and
7C), suggesting that compound 4r has no significant toxic
effect at this dosage. However, the growth of tumor
xenografts were significantly inhibited by 4r treatment (FIG.
7D).
Therefore, as shown in this example, the halogenated stilbene analogs of the present disclosure are capable of inhibiting CRC both in vitro and in vivo. In another study, it was
shown that mice could tolerate at least 200 mg/kg of a halogenated stilbene analog, FIDAS 4dd. The body weights in
these mice were reduced after one week but were recovered to
normal weight after stopping 4dd treatment (data not shown).
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Example 7
Halogenated Stilbene Analogs Inhibit Wnt Signaling
in the Nucleus
The stilbene analogs of the present disclosure and in particular, (E)-4-(2,6-difluorostyryl)-N,N -diethylaniline (compound 4s) (FIG. 8) exhibit strong fluorescence at 365 nm
(FIG. SA), albeit compound 4s is slightly less active than
compound 4r (FIG. SB). Nevertheless, compound 4s lends
itself well to a mechanistic study of the site of action of these
compounds. LS174 cells were treated with 10 f.LM of compound 4s for 2 h, 6 h, 12 h, and 24 h. The cells were fixed and
analyzed by confocal fluorescence microscopy. It was found
that compound 4s was localized throughout the nucleus and
cytoplasm at 2 h. After 12 h, the nuclear levels of compound
4s were decreased (data not shown, see Zhang eta!., J. of
Med. Chern. 54, 1288-1297 (2011)). To study the effects of
these compounds on ~-catenin localization, LS 174 cells were
treated with 10 f.LM of compound 4r for 24 h. The cells were
fixed and ~-catenin localization analyzed by immunofluorescence. The nuclear ~-catenin levels were decreased in compound 4r treated cells compared with the DMSO-treated
cells. However, significant levels of nuclear ~-catenin were
still detected in the nucleus of compound 4r treated cells,
suggesting that compound 4r may also inhibit Wnt signaling
though mechanisms other than regulating ~-catenin level and
localization. The downstream factors of ~-catenin were analyzed and it was found that the protein levels of TCF4 and
pygopus2 were reduced by compound 4r and resveratrol in
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Target Identification for Halogenated Stilbene
Analogs
Materials and Methods:
The following materials and methods have been used to
generate the results in this and other examples in the application.
Western Blot and Cell Proliferation Assay.
The activity of fluorinated N,N-dialkylaminostilbenes (FIDAS or FIDAS agents) on Wnt signaling activity in cancer
cells were analyzed by Western blot with antibodies against
Wnt target genes, such as c-Myc, Axin2 The effects ofFIDAS
agents on cancer cell growth were analyzed using Cell Viability Analyzer (Beckman Coulter, Vi-Cell XR). These assays
have been described previously (see Zhang eta!., J. ofMed.
Chern. 54, 1288-1297 (2011)).
Lentivirus-Mediated shRNA Assay.
ShRNA constructs for MAT2A and MAT2B were ordered
from Sigma. 293T cells were transfected with lentivirus packaging plasmids psPAX2 and pMD2.G, as well as control or
MAT2A/2B shRNA plasmids. Lentivirus stock was collected
48 h after transfection. HT29, LS174T and Hep3B cell lines
were infected by the lentivirus stock for 12 h, followed by
sustained growth in fresh medium for 36-48 h. Infected cell
lines were seeded in 12-well plate for proliferation assay.
ShRNA efficiency was tested by western blot using lysate
from 293T cells co-transfected with pcDNA3.1-MAT2A/2B
and pLK0.1-shRNA plasmids.
Protein Purification.
To purifY the FIDAS target, LS174T celllysates were incubated with streptavidin beads and biotinylatedFIDAS reagent
13 (see FIGS. 4 and lOA) at 4° C. overnight. The beads were
washed 3 times with cell lysis buffer. Binding proteins were
elution with 2.5 mM D-Biotin. The purified samples were
separated by 4-12% gradient SDS-PAGE and analyzed by
silver staining or Sypro Ruby fluorescent staining. The protein bands specifically presented in the samples of the biotinylated analog were excised and analyzed by LC-MS/MS as
previously described (See Zhang et a!., Novel cross talk of
Kruppel-like factor 4 and beta-catenin regulates normal intestina! homeostasis and tumor repression. Mol Cell Biol 2006,
26, 2055-64).
MAT2A and MAT2B were Cloned into pGEX6p3 Vector.
The constructs were transfected into E. coli BL21. The
GST-fusion proteins were induced by IPTG and purified by
glutathione beads as described previously (See Liu, beta-Trcp
couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Nat! A cad Sci USA 1999,
96, 6273-8). For the binding assay, purified proteins were
incubated with streptavidin beads and biotinylated FIDAS 13
described above. Eluted proteins were analyzed by western
blot with antibodies against GST, MAT2A or MAT2B.
SAM and SAHAnalysis by LC-MS/MS.
The LC-MS/MS system consisted of two Varian ProS tar
210 LC Pumps coupled with a Varian 1200L triple quadrupole mass spectrometer. The separation was performed on a
Hypercarb colunm (50 mmx2.1 mm, 3 mm, Thermo Scientific #35003-052130). Gradient elution started with 98%

US 9,132,102 B2
43

44

solution A (0.1% formic acid in water), followed by an
Example 9
increase to 38% solution B (0.1% formic acid in acetonitrile)
The Effects ofHalogenated Stilbene Analogs on
in 8 min. The colunm was than flushed with 90% B for 5 min
MAT2A Enzyme Activity
and regenerated with 98% A for another 8 min. The flow rate
was 0.25 mL/min Between the 3rd and 11th min, the eluent 5
Methionine adenosyltransferases catalyze the reaction of
was switched to the ion source of the mass spectrometer. The
S-adenoslmethionine (SAM or AdoMet) synthesis fromATP
precursor product transitions for SAM (m/z 399~ 250), SAH
and L-methionine. In mannnals, there are three types of
(m/z 385~250) and [d-4]-SAH (m/z 389~436) were monimethionine adenosyltransferases, MATIIIII and MATH.
tored. The optimized ion source parameters were: Capillary
MATI and III are tetramer or dimer of a! subunit (encoded by
Voltage: 32 V for both SAM and SAH, Collision energy: 9 V 10
MAT1A) and are expressed in adult liver. MAT2A encodes
and 7V for SAM and SAH, respectively, Needle voltage:
the catalytic subunit (a2) of type II methionine adenosyl5000 V and the Shield voltage: 600V. Nitrogen was used as
transferases. MAT2B encodes the regulating subunit of a2.
the drying gas at a temperature of 300° C. and the interface
MAT2A and MAT2B are widely expressed in proliferating
heater was set to 50° C. The drying gas and nebulizing gas
cells and cancers. MAT2A controls the cellular levels of
were set to 20 and 50 psi, respectively.
15 SAM, which is the major methyl donor for many cellular
Cell Based SAM Analysis.
methylation reactions, including DNA methylation and proLS174T cells were cultured in RPMI1640 medium contein methylation.
taining 5% FBS. Cells were treated with FIDAS reagents for
To test ifFIDAS reagents inhibit the enzymatic activity of
24 h or 48 hours. Cells were harvested and weighted. PerMAT2A, an LC-MS/MS method was developed to detect and
chloric acid (0.4M) was added to cell pellet (1 00 fll/1 0 mg) for 20 analyze AdoMet (SAM) and SAH (S-adenosylhomocysdeproteinization. The sample was mixed vigorously and centeine) (data not shown). Furthermore, an in-vitro method was
trifuged at 10,000 g. 60 fll supernatant was mixed with 20 fll
developed to synthesize SAM from L-methionine and ATP.
internal standard (5 flg/ml of SAH-d4 ). Sample was adjusted
The results show that both resveratrol and compound 4r
to pH 5-7 with 2.5 M K 2 HP04 and kept on ice for 15 min to
inhibit MAT2A activity in SAM synthesis, and that 10 f.LM of
precipitate potassium perchlorate. Samples were centrifuged 25 compound 4r reduces MAT2A activity in LS174 cells more
twice at 10000 g for 15 min. 5 ul of supernatants were anasignificantly than 30 f.LM of resveratrol. These data suggest
lyzed by LC-MS/MS using a modified method based on a
that 4r is significantly more potent than resveratrol in MAT2A
previous publication (see Krijt eta!., J Chromatogr B Analyt
inhibition (FIG. llA). A test of another halogenated stilbene
TechnolBiomedLifeSci 877,2061-6, (2009)). SAMandSAH
analog in an assay for inhibition of SAM and SAH showed
standard were prepared by serial dilutions with 0.4 M per- 30 that compound 4dd was even more potent than 4r in inhibition
chloric acid (PCA), the individual calibration points were
ofMAT2A and reduction of SAM and SAH (FIGS. llB and
0.05, 0.5, 5, 50 f.tg/ml.
llC). In FIGS. llB and llC, the effects of3 f.LM of 4dd was
SAM Synthesis.
compared with the 10 uM of 4r and 30 uM of resveratrol in
5 mg purified MAT2A was incubated with 1 mM L-mecausing reduction in SAM and SAH concentrations, respecthionine and 1 mMATP in 500 ml reaction solution (50 mM 35 tively. These results show that compound 4dd is even more
Tris.Cl, 50 mM KCI, 10 mM MgCI2) for 5 min at 25° C. The
potent than compound 4r which is significantly more potent
reaction was stopped with 500 ml 0.4 M Perchloric acid and
than resveratrol.
neutralized with 2.5 M K2HP04. The samples were kept on
ice for 15 min to precipitate potassium perchlorate as
Example 10
described above. SAM was analyzed by LC-MS/MS.
40
In this example, by using the biotinylated compounds of
The Effects of MAT2A and MAT2B Genes
the present disclosure, it was possible to purify and identify
Inhibition on Cell Proliferation
methionine adenosyltransferase 2A (MAT2A) as the direct
target for the halogenated stilbene analogs described herein.
In this example, the effects of inhibition of MAT2A and
CRC cell lysates were incubated with streptavidin 45 MAT2B genes on cell proliferation were studied. To study the
beads±biotin-FIDAS (FIG. 9A) and binding proteins were
biological function ofMAT2A and MAT2B in cell proliferaelution with 2.5 mM D-Biotin. The purified samples were
tion, the expression of MAT2A or MAT2B genes were
separated by 4-12% gradient SDS-PAGE and analyzed by
knocked down by shRNAs (FIGS. 12A and 12B). Both
silver staining (FIG. 9B). Two specific protein bands were
MAT2A and MAT2B shRNAs inhibited proliferation ofliver
identified. These bands were analyzed by MALDI-TOF/TOF so cancer cells Hep3B (FIG. 12C). To test if MAT2A and
and LC-MS/MS mass spectrometry methods. These two
MAT2B are required for colon cancer cell proliferation,
bands were identified to be methionine adenosyltransferase
MAT2A and MAT2B genes were knocked down in colon
2A (MAT2A), the upper band, and methionine adenosyltranscancer cells, LS174T and HT29. In a time-course study for
ferase 2B (MAT2B), the lower band, by both methods (FIG.
the effects of MAT2A and MAT2B inhibition on cell prolif9B).
55 eration in LS174T and HT29, it was determined that both
Since MAT2A and MAT2B bind each other and form a
MAT2A and MAT2B shRNAs inhibit proliferation of colon
complex, to determine which subunit directly interacts with
cancer cells, and that inhibition ofMAT2A is more effective
FIDAS reagents, recombinant MAT2A and MAT2B were
in inhibition of cancer cell proliferation than inhibition of
purified and tested for interaction with FIDAS. Briefly, GSTMAT2B (FIGS. 13A and 13B).
MAT2A and GST-MAT2B fusion proteins were expressed 60
and purified from E. coli. These proteins were incubated with
Example 11
streptavidin beads with or without biotinylated derivative 13
(FIG. 9A). The binding proteins were eluted by 2.5 mM
The Effects the Metabolites of the Halogenated
D-biotin and analyzed by Western blot with an anti-GST-Ab.
Stilbene Analogs on Cell Proliferation In-Vitro
It was found MAT2A directly binds to biotinylated FIDAS 65
reagents; MAT2B binds FIDAS reagents indirectly through
As previously shown, several metabolites of the halogeMAT2A (FIG. 10).
nated stilbenes of the present disclosure were synthesized
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(Example 2 and FIG. 3). In this study, the effects of some of
these metabolites on cell proliferation were studied. Compounds 4aa, 4dd and 4ee were significantly more effective
than resveratrol, as well as compound 4r (FIGS. 14 and 15).

Example 14
Binding Studies of MAT2A and Halogenated
Stilbene Analogs

Example 12
The Effects the Metabolites of the Halogenated
Stilbene Analogs on Cell Proliferation In-Vivo in
Mice
In this study, the oral efficacy of the metabolites of halogenated stilbene analogs were tested in mice.
Xenografted nude mice were developed according to the
protocol described above and in Zhang et a!., J. of Med.
Chern. 54, 1288-1297 (2011)). Briefly, HT29 cells were
injected subcutaneously into the flanks of nude mice. The
mice were then treated with 20 mg/kg compound 4dd dissolved in PEG400 by gavage. As described in Example 7, an
IP injection of compound 4r dissolved in corn oil inhibited
xenograft tumor growth. Here, it was also shown that the
halogenated stilbenes of the present disclosure can also be
dissolved in other solvents such as PEG400 and cycledextran.
The results show that 4dd significantly inhibits the growth
of xenografted tumors without any adverse effect on body
weight (FIG. 16).
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Example 15
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Example 13
30

Halogenated Stilbene Analogs Inhibit Other Cancer
Types
As discussed above, the halogenated stilbene analogs of
the present disclosure bind to MAT2A and inhibit the enzyme
function which leads to inhibition of colon cancer cell proliferation. Since, for example, in liver cancer, it has been shown
that the expression ofMAT1A is decreased while the expression ofMAT2A is increased (see Cai eta!., Hepatology 24,
1090-7 (1996) ), Applicants hypothesized that the compound
of the disclosure should inhibit proliferation of other types of
cancers, particularly those in which the MAT2A activity or
expression is increased.
To test this hypothesis, a number cancer cell lines were
treated with the halogenated stilbene analogs of the present
disclosure. The results show that the halogenated stilbene
analogs are capable of inhibiting other cancer types as well.
As showninFIG.17, the compounds of the present disclosure
inhibited cell proliferation ofbreast cancer (FIG. 17A), lung
cancer (FIGS. 17B and C), carcinoid tumor (FIG. 17D) and
prostate cancer (FIG. 17E) cell lines.

To test if the halogenated stilbene analogs of the present
disclosure also bind MATlA, a His-tagged MATlA was
cloned in and purified from E. coli. An in vitro binding assay
was performed, and the results show that the compounds
tested only bound to MAT2A but not MATlA (FIG. 18B).
According to published MAT structures, several key residues
are involved in substrate binding and catalysis. Among these
key residues, lysine 265 is conserved between MAT1A and
MAT2A and among different species. When lysine 265 was
mutated to leucine (K265 L, FIG. 18A), the binding between
MAT2A and compound 13 was significantly decreased, suggesting that K265 is involved in binding with compounds of
the present disclosure (FIG. 18C). Taken together, the FIDAS
reagents are specific inhibitors ofMAT2A, and are promising
drug candidates for multiple cancers as well as metabolic
diseases.

35

40

45

The Efficacy ofthe Halogenated Stilbene Analogs in
Inhibiting Other MAT2A-Related Diseases or
Disorders
It has also been shown that MAT2A is induced by hepatitis
B infection in the liver Liuetal.,J. Biol. Chern. 286, 17168-80
(2011)). Since the compounds of the present disclosure are
effective in inhibiting MAT2A and reducing SAM, these
compounds must be effective in treating any disease or condition in which MAT2A may be involved, including, but not
limited to, metabolic disorders such as diabetes, heart disease,
aging, obesity, and neurodegenerative disease, such as Alzheimer's and Parkinson diseases
Only the preferred embodiment of the present disclosure
and examples of its versatility are shown and described in the
present disclosure. It is to be understood that the present
disclosure is capable of use in various other combinations and
environments and is capable of changes or modifications
within the scope of the inventive concept as expressed herein.
Thus, for example, those skilled in the art will recognize, or be
able to ascertain, using no more than routine experimentation,
numerous equivalents to the specific substances, procedures
and arrangements described herein. Such equivalents are considered to be within the scope of this disclosure, and are
covered by the following claims. Any or all patents and/or
publications including journal articles cited in this disclosure
are expressly incorporated herein by reference.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 18
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 18
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, B-Actin primer

<400> SEQUENCE, 1
Cys Ala Ala Cys Cys Gly Cys Gly Ala Gly Ala Ala Gly Ala Thr Gly
1
5
10
15
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48
-continued

Ala Cys

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 18
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, B-actin primer

<400> SEQUENCE, 2
Ala Gly Gly Ala Ala Gly Gly Cys Thr Gly Gly Ala Ala Gly Ala Gly
1
5
10
15
Thr Gly

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 22
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, survivin primer

<400> SEQUENCE, 3
Cys Ala Thr Thr Cys Gly Thr Cys Cys Gly Gly Thr Thr Gly Cys Gly
1
5
10
15
Cys Thr Thr Thr Cys Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 4
LENGTH, 22
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, survivin primer

<400> SEQUENCE, 4
Gly Cys Gly Cys Ala Cys Thr Thr Thr Cys Thr Cys Cys Gly Cys Ala
1
5
10
15
Gly Thr Thr Thr Cys Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 5
LENGTH, 19
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, c-Myc primer

<400> SEQUENCE, 5
Thr Gly Gly Gly Cys Thr Gly Thr Gly Ala Gly Gly Ala Gly Gly Thr
1
5
10
15
Thr Thr Gly

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 6
LENGTH, 19
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, c-Myc primer

<400> SEQUENCE,
Thr Ala Thr Gly Thr Gly Gly Ala Gly Cys Gly Gly Cys Thr Thr Cys
1
5
10
15
Thr Cys Gly
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49
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 7
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, axin2 primer

<400> SEQUENCE,

7

Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys
1
5
10
15
Ala Thr Thr Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 8
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, axin2 primer

<400> SEQUENCE,

8

Gly Cys Ala Thr Cys Cys Ala Cys Thr Gly Cys Cys Ala Gly Ala Cys
1
5
10
15
Ala Thr Cys Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 9
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, TCF4 primer

<400> SEQUENCE,

9

Cys Ala Cys Cys Ala Cys Ala Thr Cys Ala Thr Ala Cys Gly Cys Thr
1
5
10
15
Ala Cys Ala Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 10
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, TCF4 primer

<400> SEQUENCE,

10

Cys Gly Ala Cys Cys Thr Thr Thr Gly Cys Thr Cys Thr Cys Ala Thr
1
5
10
15
Thr Thr Cys Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 11
LENGTH, 19
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, pygopus2 primer

<400> SEQUENCE,

11

Gly Gly Cys Cys Gly Gly Thr Cys Thr Gly Cys Ala Ala Ala Thr Gly
1
5
10
15
Ala Ala Gly
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<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 12
LENGTH, 19
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, pygopus2 primer

<400> SEQUENCE,

12

Thr Cys Cys Ala Cys Cys Thr Cys Cys Ala Gly Thr Gly Cys Thr Gly
1
5
10
15
Thr Ala Gly

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 13
LENGTH, 22
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Lgr5 primer

<400> SEQUENCE,

13

Cys Cys Thr Gly Cys Thr Thr Gly Ala Cys Thr Thr Thr Gly Ala Gly
1
5
10
15
Gly Ala Ala Gly Ala Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 14
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Lgr5 primer

<400> SEQUENCE,

14

Ala Thr Gly Thr Thr Cys Ala Cys Thr Gly Cys Thr Gly Cys Gly Ala
1
5
10
15
Thr Gly Ala Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 15
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, CD44 primer

<400> SEQUENCE,

15

Cys Ala Gly Ala Ala Thr Gly Gly Cys Thr Gly Ala Thr Cys Ala Thr
1
5
10
15
Cys Thr Thr Gly
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 16
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, CD44 primer

<400> SEQUENCE,

16

Cys Ala Ala Ala Thr Gly Cys Ala Cys Cys Ala Thr Thr Thr Cys Cys
1
5
10
15
Thr Gly Ala Gly
20

US 9,132,102 B2
54

53
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 17
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Ki67 primer

<400> SEQUENCE, 17
Ala Cys Ala Gly Ala Gly Thr Gly Cys Thr Cys Ala Ala Cys Ala Ala
1
5
10
15
Cys Thr Thr Cys
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 18
LENGTH, 20
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Ki67 primer

<400> SEQUENCE, 18
Gly Cys Thr Thr Gly Cys Ala Gly Ala Gly Cys Ala Thr Thr Thr Ala
1
5
10
15
Thr Cys Ala Gly
20

30
What is claimed is:
2. The method according to claim 1, whereinAr2 is pyridyl
substituted with alkylamino, or dialkylamino.
1. A method of treating liver cancer or colon cancer, the
3. The method according to claim 1, wherein X is one, two
method comprising administering to a patient in need of such
or three fluorine and/ or chlorine on Ar 1 .
treatment an effective amount of a compound according to
4. The method according to claim 1, wherein X represents
formula (I):
35 at least one fluorine and at least one chlorine on Ar 1 .
(I)
5. The method according to claim 1, wherein, X is one or
more fluorine and/or chlorine.
or a pharmaceutically acceptable salt thereof, wherein Ra
6. The method according to claim 1, wherein Rc is H or a
and R6 are independently H, alkyl, halo, alkoxy, cyano;
lower alkyl and Rd is a lower unsubstituted alkyl.
X represents at least one halogen onAr 1 ; Ar 1 is phenyl
40
7. The method according to claim 1, wherein X is one or
andAr2 is pyridyl; provided thatAr2 contains at least one
more fluorine and/or chlorine and Rc isH or a lower alkyl and
NRcRdz substituent onAr2 where Rc isH, alkyl, alkoxy,
Rdis a lower unsubstituted alkyl.
aryl, heteroaryl, Rd is an unsubstituted alkyl group, Z is

an unshared pair of electrons, H, alkyl, oxygen.

* * * * *

